Anti-coronavirus compound as well as composition and application thereof

By developing novel (I) compounds, the problems of low oral bioavailability and poor oxidase tolerance of existing 3CLpro inhibitors have been solved, achieving effective inhibition of 3CL protease and improved drug stability.

CN118909031AActive Publication Date: 2024-11-08SHANGHAI CUREGENE PHARM CO LTD

Patent Information

Application Number
CN202410957523.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-06-24
Filing Date
2022-12-29
Publication Date
2024-11-08
Estimated Expiration
2042-12-29

AI Technical Summary

Technical Problem

Existing 3CLpro inhibitors, such as PF-07304814 and PF-07321332, have low oral bioavailability and poor tolerance to oxidases, and need to be used in combination with oxidase inhibitors to effectively combat SARS-CoV-2.

Method used

A novel compound with the structure of formula (I) has been developed, which can covalently bind to 3CL protease, exhibits good oral bioavailability and high oxidase tolerance, and can be used as an antiviral drug.

Benefits of technology

This compound can effectively inhibit 3CL protease, showing high tolerance to oxidases, reducing dependence on oxidase inhibitors, and improving the metabolic stability and therapeutic effect of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_7
    Figure SMS_7
  • Figure SMS_8
    Figure SMS_8
Patent Text Reader

Abstract

The present disclosure relates to compounds that exhibit activity in the inhibition of chymotrypsin-like proteases, as well as pharmaceutical compositions comprising these compounds and methods of treating viral infections by administering these compounds or pharmaceutical compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application with application number 202280075597.9, application date December 29, 2022, and invention name “Anti-coronavirus compounds, compositions and uses thereof”. The original application is a national phase application of the international application with international application number PCT / CN2022 / 143464, which claims priority to the international application PCT / CN2021 / 142604 filed on December 29, 2021 and the international application PCT / CN2022 / 101118 filed on June 24, 2022. Field of the Invention

[0002] The present disclosure relates generally to compounds that exhibit activity in inhibiting 3-chymotrypsin-like proteases and pharmaceutical compositions comprising these compounds, as well as methods of treatment by administering these compounds or pharmaceutical compositions comprising these compounds. Background Art

[0003] Coronaviruses are highly susceptible to mutating into pandemic variants. Although multiple vaccines have been approved for use since the SARS-CoV-2 outbreak, vaccinated individuals are still at risk of the emergence of immune-escape mutants. Therefore, it is extremely important to develop antiviral drugs to combat existing and emerging coronaviruses.

[0004] The coronavirus 3-chymotrypsin-like protease (3CLpro; also known as the “main protease” or “Mpro”) is an attractive drug target because it plays an important role in processing polyproteins translated from viral RNA. It cleaves two large overlapping polyproteins, ppla and pplab, at more than 11 sites to produce essential nonstructural proteins required for viral replication and pathogenesis. This cleavage process is facilitated by the Cys145-His41 catalytic dyad located in the cleft between domains I and II of 3CLpro. The Cys145-His41 catalytic dyad and substrate binding site are highly conserved among different species of coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), which emerged in 2002 and 2012, respectively. Therefore, 3CLpro inhibitors are promising broad-spectrum antiviral agents for coronavirus infections and other related diseases.

[0005] Pfizer has developed two 3CLpro inhibitors, PF-07304814 and PF-07321332 (nematevir). Even with the addition of an oxidase inhibitor, PF-07304814 still exhibits fairly low oral bioavailability and low tolerance to oxidases. PF-07321332 did not overcome the problem of low tolerance to oxidases, so it needs to be co-administered with the oxidase inhibitor ritonavir tablets to be effective against SARS-CoV-2.

[0006] Therefore, there is a need in the art to develop improved compounds that exhibit inhibitory activity against 3CLpro, particularly 3CLpro inhibitors with good oral bioavailability and high tolerance to oxidative enzymes. Summary of the invention

[0007] The present disclosure provides compounds capable of inhibiting 3-chymotrypsin-like proteases, pharmaceutical compositions comprising these compounds, and methods of using such compounds or pharmaceutical compositions to treat viral infections.

[0008] In one aspect, the present disclosure provides a compound having formula (I'):

[0009]

[0010] or a pharmaceutically acceptable salt thereof,

[0011] in

[0012] R 1 and R 2 are each independently hydrogen, halogen or alkyl, the alkyl being optionally substituted by one or more groups independently selected from halogen, hydroxy, cyano, amino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, or

[0013] R 1 and R 2 Together with the carbon atom to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl;

[0014] Optionally one or more R a replace;

[0015] Each R a is selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl, alkynyl or haloalkyl, or

[0016] Two R's atogether with the carbon atom to which they are attached, form a cycloalkyl or heterocyclyl group, which may be optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl;

[0017] L is selected from *-L 1 -or*-L 2 -(CH2) q -L 3 -,

[0018] L 1 and L 2 Each independently selected from the group consisting of: a bond, *-N(R b )-, *-O-, *-S-, *-CR b =CR c -,*-C≡C-,*-S(O)-,*-SO2-, *-ZC(O)-Z- and The * end of L is The * end connection;

[0019] L 3 Selected from bonds, -N(R b )-、-O-、-S-、-CR b =CR c -, -C≡C-, -S(O)- or -SO2-,

[0020] Each V is independently selected from CR b or N, each Z is independently selected from a bond, -CR b R c -, -O- or -N(R b )-;R b and R c are each independently selected from hydrogen, halogen, alkyl or haloalkyl;

[0021] Ring A is a 5-membered or 6-membered heterocyclic group;

[0022] Each R 3 is independently hydrogen, halogen or alkyl, the alkyl being optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino, alkenyl or alkynyl, or

[0023] One or two pairs of R 3 each together with the carbon atom to which they are attached form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl or alkynyl;

[0024] R 4A warhead that can covalently bind to 3CL protease;

[0025] G is C or Si;

[0026] R 5A , R 5B and R 6 are each independently selected from hydrogen, halogen, -OR d , alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl are optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy or haloalkyl, and R d is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkylaryl, alkylcycloalkyl, alkylheterocyclyl, alkylheteroaryl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or

[0027] R 5A and R 5B Together with the G atom to which they are attached, they form a cycloalkyl or heterocyclyl group, wherein the cycloalkyl and heterocyclyl groups are optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl; or

[0028] R 5B and R 6 together with the atoms to which they are attached form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl;

[0029] R 7 For-R 7-1 -R 7-2 , where R 7-1 Selected from a bond, -C(O)O-**, -C(O)-**, -C(O)N(R b )-** or -SO2-**, R 7-2is selected from hydrogen, halogen, alkyl, haloalkyl, alkoxy, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, alkenylcycloalkyl, alkenylheterocyclyl, alkenylaryl, alkenylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said alkyl, alkoxy, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, alkenylcycloalkyl, alkenylheterocyclyl, alkenylaryl, alkenylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy, haloalkyl or -C(O)CF3, wherein R 7-1 The ** end is connected to R 7-2 ;

[0030] R 8 is selected from hydrogen, halogen, alkyl or haloalkyl; or

[0031] R 7 and R 8 Together with the nitrogen atom to which they are attached, they form a heterocyclic group, which is optionally substituted by one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl;

[0032] R 9 is selected from hydrogen, methyl or ethyl;

[0033] m is 0, 1, 2, 3, or 4;

[0034] n is 0, 1, 2, 3, or 4;

[0035] p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; and

[0036] q is 0, 1, or 2.

[0037] In another aspect, a compound having formula (I) or (II) is provided:

[0038]

[0039]

[0040] or a pharmaceutically acceptable salt thereof.

[0041] In yet another aspect, a compound having formula (III) is provided:

[0042]

[0043] or a pharmaceutically acceptable salt thereof.

[0044] In yet another aspect, provided are compounds having formula (IIIa) or (IIIb):

[0045]

[0046] or a pharmaceutically acceptable salt thereof.

[0047] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0048] In another aspect, the present disclosure provides a method for treating a viral infection in a patient in need thereof, comprising administering to the subject an effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0049] In another aspect, the present disclosure provides a method of inhibiting 3-chymotrypsin-like protease in a subject in need thereof, comprising administering to the subject in need thereof an effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0050] In another aspect, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present disclosure in the preparation of a medicament for treating a viral infection.

[0051] In another aspect, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present disclosure for use in treating viral infection. DETAILED DESCRIPTION

[0052] For details, please refer to certain embodiments of the present disclosure, examples of which are illustrated in the accompanying structures and formulas. Although the present disclosure will be described in conjunction with the enumerated embodiments, it should be understood that it is not intended that the present disclosure will be limited to those embodiments. On the contrary, the present disclosure is intended to cover all alternatives, modifications or equivalents, which may be included within the scope of the present disclosure as defined by the claims. Those skilled in the art will recognize that many methods or materials that can implement the present disclosure are similar or equivalent to those methods or materials described herein. The present disclosure is in no way limited to the methods or materials described. In the event that one or more of the incorporated references and similar materials (including but not limited to defined terms, term usage, the technology, etc.) are different from or contradictory to the present application, the present disclosure shall prevail. All references, patents, and patent applications cited in the present disclosure are incorporated herein by reference in their entirety.

[0053] It should be understood that certain features of the disclosure described in the context of different embodiments for the sake of clarity may also be provided in combination in a single embodiment. Conversely, various features of the disclosure described in the context of a single embodiment for the sake of brevity may also be provided separately or in any suitable sub-combination. It must be noted that, as used in the specification and the appended claims, the singular forms "a / an" and "the" include their plural forms unless the context clearly dictates otherwise. Thus, for example, a reference to a "compound" includes a plurality of compounds.

[0054] definition

[0055] Definitions of specific functional groups and chemical terms are described in more detail below.For purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th ed., inside cover, and specific functional groups are generally defined as described therein. In addition, general principles of organic chemistry as well as specific functional groups and reactivity are described in Organic Chemistry, Thomas Sorrell, 2nd edition, University Science Books, Sausalito, 2006; Smith and March, March's Advanced Organic Chemistry, 6th edition, John Wiley & Sons, Inc., New York, 2007; Larock, Comprehensive Organic Transformations, 3rd edition, VCH Publishers, Inc., New York, 2018; Carruthers, Some Modern Methods of Organic Synthesis, 4th edition, Cambridge University Press, Cambridge, 2004; the entire contents of each of which are incorporated herein by reference.

[0056] In various places of this disclosure, linking substituents are described. In particular, each linking substituent is intended to include both the forward and reverse forms of the linking substituent. For example, -NR(CR'R")- includes both -NR(CR'R")- and -(CR'R")NR-. Where a structure clearly requires a linking group, the Markush variable listed for that group is to be understood as a linking group. For example, if a structure requires a linking group and the Markush group definition of the variable lists "alkyl", then it is to be understood that the "alkyl" represents a linking alkylene group.

[0057] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then the substituent may be bonded to any atom on the ring. When a substituent is listed without indicating that the substituent is bonded to an atom in the remainder of a compound of a given formula, then the substituent may be bonded via any atom in the formula. Combinations of substituents and / or variables are permissible, but only if the combinations result in stable compounds.

[0058] When "*" is shown adjacent to an atom of a compound, it indicates that the compound contains the atom as an asymmetric center in either the (R) or (S) stereoconfiguration.

[0059] When any variable (such as R i ) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown as having 0-2 R i If the group is partially substituted, then the group may be optionally substituted with up to two R i Partially substituted, and R i In each occurrence, independently selected from i Also, combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0060] As used herein, the term “C i-j " indicates a range of carbon atoms, wherein i and j are integers, and the range of carbon atoms includes the endpoints (i.e., i and j) and every integer point therebetween, and wherein j is greater than i. For example, C 1-6 Indicates a range of one to six carbon atoms, including one carbon atom, two carbon atoms, three carbon atoms, four carbon atoms, five carbon atoms, and six carbon atoms. In some embodiments, the term "C 1-12 ” indicates 1 to 12, especially 1 to 10, especially 1 to 8, especially 1 to 6, especially 1 to 5, especially 1 to 4, especially 1 to 3 or especially 1 to 2 carbon atoms.

[0061] As used herein, the term "alkyl", whether used as part of another term or independently, refers to a saturated straight or branched chain hydrocarbon group, which may be optionally substituted independently with one or more substituents as described below. i-j "Alkyl" refers to an alkyl group having i to j carbon atoms. In some embodiments, the alkyl group contains 1 to 10 carbon atoms. In some embodiments, the alkyl group contains 1 to 9 carbon atoms. In some embodiments, the alkyl group contains 1 to 8 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 5 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. "C 1-10 Examples of "alkyl" include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl. 1-6 Examples of "alkyl" are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, and the like.

[0062] As used herein, the term "alkylcycloalkyl" refers to an alkyl group attached to a cycloalkyl group, including -alkyl-cycloalkyl and alkyl-cycloalkyl-. In some embodiments, alkylcycloalkyl refers to -alkyl-cycloalkyl.

[0063] As used herein, the term "alkylheterocyclyl" refers to an alkyl group attached to a heterocyclyl group, including -alkyl-heterocyclyl and alkyl-heterocyclyl-. In some embodiments, alkylheterocyclyl refers to -alkyl-heterocyclyl.

[0064] As used herein, the term "alkylaryl" refers to an alkyl group attached to an aryl group, including -alkyl-aryl and alkyl-aryl-. In some embodiments, alkylaryl refers to -alkyl-aryl.

[0065] As used herein, the term "alkylcycloalkyl" refers to an alkyl group attached to an aryl group, including -alkyl-cycloalkyl and alkyl-cycloalkyl-. In some embodiments, alkylcycloalkyl refers to -alkyl-cycloalkyl.

[0066] As used herein, the term "alkylheteroaryl" refers to an alkyl group attached to a heteroaryl group, including -alkyl-heteroaryl and alkyl-heteroaryl-. In some embodiments, alkylheteroaryl refers to -alkyl-heteroaryl.

[0067] As used herein, the term "alkenyl", whether used as part of another term or independently, refers to a straight or branched hydrocarbon group having at least one carbon-carbon double bond, which may be optionally substituted independently with one or more substituents as described herein, and includes groups having "cis" and "trans" configurations, or alternatively, "E" and "Z" configurations. In some embodiments, the alkenyl group contains 2 to 12 carbon atoms. In some embodiments, the alkenyl group contains 2 to 11 carbon atoms. In some embodiments, the alkenyl group contains 2 to 11 carbon atoms, 2 to 10 carbon atoms, 2 to 9 carbon atoms, 2 to 8 carbon atoms, 2 to 7 carbon atoms, 2 to 6 carbon atoms, 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, and in some embodiments, the alkenyl group contains 2 carbon atoms. Examples of alkenyl groups include, but are not limited to, ethylenyl / vinyl, propenyl (allyl), butenyl, pentenyl, 1-methyl-2-but-1-enyl, 5-hexenyl, and the like.

[0068] As used herein, the term "alkenylcycloalkyl" refers to an alkenyl group attached to a cycloalkyl group, including -alkenyl-cycloalkyl and alkenyl-cycloalkyl-. In some embodiments, alkenylcycloalkyl refers to -alkenyl-cycloalkyl.

[0069] As used herein, the term "alkenylheterocyclyl" refers to an alkenyl group connected to a heterocyclyl group, including -alkenyl-heterocyclyl and alkenyl-heterocyclyl-. In some embodiments, alkenylheterocyclyl refers to -alkenyl-heterocyclyl.

[0070] As used herein, the term "alkenylaryl" refers to an alkenyl group attached to an aryl group, including -alkenyl-aryl and alkenyl-aryl-. In some embodiments, alkenylaryl refers to -alkenyl-aryl.

[0071] As used herein, the term "alkenylheteroaryl" refers to an alkenyl group attached to a heteroaryl group, including -alkenyl-heteroaryl and alkenyl-heteroaryl-. In some embodiments, alkenylheteroaryl refers to -alkyl-heteroaryl.

[0072] As used herein, the term "alkoxy" refers to an alkyl group (-O-alkyl) connected to oxygen, whether as part of another term or used independently. In some embodiments, the alkoxy group contains 1 to 10 carbon atoms. In some embodiments, the alkoxy group contains 1 to 9 carbon atoms. In some embodiments, the alkoxy group contains 1 to 8 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 5 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, isopropoxy, etc.

[0073] As used herein, the term "alkynyl" refers to a straight or branched hydrocarbon group having at least one carbon-carbon triple bond, whether used as part of another term or independently, which may be optionally substituted independently with one or more substituents described herein. In some embodiments, the alkynyl group contains 2 to 12 carbon atoms. In some embodiments, the alkynyl group contains 2 to 11 carbon atoms. In some embodiments, the alkynyl group contains 2 to 11 carbon atoms, 2 to 10 carbon atoms, 2 to 9 carbon atoms, 2 to 8 carbon atoms, 2 to 7 carbon atoms, 2 to 6 carbon atoms, 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, and in some embodiments, the alkynyl group contains 2 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, and the like.

[0074] As used herein, the term "amino" refers to a -NH2 group. The amino group may also be substituted with one or more groups such as alkyl, aryl, carbonyl or other amino groups.

[0075] As used herein, the term "aryl", whether used as part of another term or independently, refers to monocyclic and polycyclic ring systems having a total of 5 to 20 ring members, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 3 to 12 ring members. Examples of "aryl" include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, and the like, which may bear one or more substituents. As used herein, groups in which an aromatic ring is fused to one or more additional rings are also included within the scope of the term "aryl". In the case of a polycyclic ring system, only one ring is required to be aromatic (e.g., 2,3-dihydroindole), although all rings may be aromatic (e.g., quinoline). The second ring may also be fused or bridged. Examples of polycyclic aryl groups include, but are not limited to, benzofuranyl, indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. Aryl groups may be substituted at one or more ring positions with substituents as described above.

[0076] Whether used as part of another term or independently, as used herein, the term "cycloalkyl" refers to monovalent non-aromatic, saturated or partially unsaturated monocyclic and polycyclic ring systems, wherein all ring atoms are carbon, and the ring system contains at least three ring-forming carbon atoms. In some embodiments, the cycloalkyl may contain 3 to 12 ring-forming carbon atoms, 3 to 10 ring-forming carbon atoms, 3 to 9 ring-forming carbon atoms, 3 to 8 ring-forming carbon atoms, 3 to 7 ring-forming carbon atoms, 3 to 6 ring-forming carbon atoms, 3 to 5 ring-forming carbon atoms, 4 to 12 ring-forming carbon atoms, 4 to 10 ring-forming carbon atoms, 4 to 9 ring-forming carbon atoms, 4 to 8 ring-forming carbon atoms, 4 to 7 ring-forming carbon atoms, 4 to 6 ring-forming carbon atoms, 4 to 5 ring-forming carbon atoms. Cycloalkyl may be saturated or partially unsaturated. Cycloalkyl may be substituted. In some embodiments, the cycloalkyl may be a saturated cyclic alkyl. In some embodiments, the cycloalkyl group may be a partially unsaturated cyclic alkyl group containing at least one double bond or triple bond in its ring system. In some embodiments, the cycloalkyl group may be monocyclic or polycyclic. Examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl. Examples of polycyclic cycloalkyl groups include, but are not limited to, adamantyl, norbornyl, fluorenyl, spiro-pentadienyl, spiro[3.6]-decyl, bicyclo[1,1,1]pentenyl, bicyclo[2,2,1]heptenyl, and the like.

[0077] As used herein, the term "cyano" refers to -CN.

[0078] As used herein, the term "halogen" refers to an atom selected from fluorine (fluorine / fluoro), chlorine (chlorine / chloro), bromine (bromine / bromo) and iodine (iodine / iodo).

[0079] As used herein, the term "haloalkyl" refers to an alkyl group substituted with one or more halogens. In some embodiments, the haloalkyl group may contain 1 to 6 carbon atoms. In some embodiments, the haloalkyl group may contain 1 to 4 carbon atoms. In some embodiments, the haloalkyl group may contain 1 to 3 carbon atoms. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, fluoromethyl, chloromethyl, dichloromethyl, dibromomethyl, tribromomethyl, and tetrafluoroethyl.

[0080] As used herein, the term "heteroatom" refers to nitrogen, oxygen, sulfur, phosphorus or silicon, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen (including N-oxides).

[0081] As used herein, the term "heteroalkyl" refers to an alkyl group in which at least one carbon atom is substituted by a heteroatom selected from N, O, S, P or Si. A heteroalkyl group can be a carbon group or a heteroatom group (i.e., a heteroatom can appear in the middle or at the end of the group), and can be optionally substituted independently by one or more substituents described herein. The term "heteroalkyl" includes alkoxy radicals and heteroalkoxy radicals.

[0082] As used herein, the term "heteroalkylaryl" refers to a heteroalkyl group attached to an aryl group, including -heteroalkyl-aryl and heteroalkyl-aryl-. In some embodiments, the heteroalkylaryl group refers to -heteroalkyl-aryl.

[0083] As used herein, the term "heteroalkylcycloalkyl" refers to a heteroalkyl group attached to a cycloalkyl group, including -heteroalkyl-cycloalkyl and heteroalkyl-cycloalkyl-. In some embodiments, heteroalkylcycloalkyl refers to -heteroalkyl-cycloalkyl.

[0084] As used herein, the term "heteroalkylheteroaryl" refers to a heteroalkyl group attached to a heteroaryl group, including -heteroalkyl-heteroaryl or heteroalkyl-heteroaryl-. In some embodiments, heteroalkylheteroaryl refers to -heteroalkyl-heteroaryl.

[0085] As used herein, the term "heteroaryl" refers to an aryl group having one or more heteroatoms in addition to carbon atoms. The heteroaryl group may be monocyclic. Examples of monocyclic heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, benzofuranyl, and pteridinyl. Heteroaryl also includes polycyclic groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclic rings, wherein the linking group or point of attachment is located on the heteroaromatic ring. Examples of polycyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, benzothiophenyl, benzofuranyl, benzo[1,3]dioxolyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, dihydroquinolyl, dihydroisoquinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, and the like.

[0086] As used herein, the term "heterocyclic group" refers to a saturated or partially unsaturated carbocyclic group, wherein one or more ring atoms are independently selected from oxygen, sulfur, nitrogen, phosphorus, etc., and the remaining ring atoms are carbon, wherein one or more ring atoms may be optionally independently substituted by one or more substituents. In some embodiments, the heterocyclic group is a saturated heterocyclic group. In some embodiments, the heterocyclic group is a partially unsaturated heterocyclic group having one or more double bonds in its ring system. In some embodiments, the heterocyclic group may contain any oxidized form of carbon, nitrogen or sulfur and any quaternized form of basic nitrogen. "Heterocyclic group" also includes groups in which the heterocyclic group is fused to a saturated, partially unsaturated or completely unsaturated (i.e., aromatic) carbocyclic or heterocyclic ring. Where possible, the heterocyclic group may be carbon-connected or nitrogen-connected. In some embodiments, the heterocyclic ring is carbon-connected. In some embodiments, the heterocyclic ring is nitrogen-connected. For example, a group derived from pyrrole may be pyrrole-1-yl (nitrogen-connected) or pyrrole-3-yl (carbon-connected). Furthermore, a group derived from imidazole may be imidazol-1-yl (nitrogen attached) or imidazol-3-yl (carbon attached).

[0087] In some embodiments, the term "3- to 12-membered heterocyclyl" refers to a 3- to 12-membered saturated or partially unsaturated monocyclic or polycyclic heterocyclic ring system having 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Fused, spiro, and bridged ring systems are also included within the scope of this definition. Examples of monocyclic heterocyclyls include, but are not limited to, oxetanyl, 1,1-dioxothietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, piperidyl, piperazinyl, piperidinyl, morpholinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, pyridonyl, pyrimidonyl, pyrazinonyl, pyridazonyl, pyrrolidinyl, triazinonyl, and the like. Examples of fused heterocyclic groups include, but are not limited to, phenyl fused rings or pyridyl fused rings, such as quinolyl, isoquinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, quinoxalinyl, quinolizinyl, quinazolinyl, azaindolizinyl, pteridinyl, chromenyl, isochromenyl, indolyl, isoindolyl, indolizinyl, indazolyl, purinyl, benzofuranyl, isobenzofuranyl, benzimidazolyl, benzothiophenyl, benzothiazolyl, carbazolyl, phenazinyl, phenothiazinyl, phenanthridinyl, imidazo[1,2-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,3]triazolo[4,3-a]pyridinyl, etc. Examples of spiro heterocyclic groups include, but are not limited to, spiropyranyl, spirooxazinyl, etc. Examples of bridged heterocyclic groups include, but are not limited to, morphanyl, hexamethylenetetramine, 3-aza-bicyclo[3.1.0]hexane, 8-aza-bicyclo[3.2.1]octane, 1-aza-bicyclo[2.2.2]octane, 1,4-diazabicyclo[2.2.2]octane (DABCO), and the like.

[0088] As used herein, the term "hydroxy" refers to -OH.

[0089] As used herein, the term "partially unsaturated" refers to a group that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic (ie, fully unsaturated) moieties.

[0090] As used herein, the term "substituted", whether or not there is the term "optionally" in front, means that one or more hydrogens of the specified part are replaced by suitable substituents. It should be understood that "replacement" or "substituted" includes the following implicit restrictions: the substitution is consistent with the allowed valence of the substituted atom, and the substitution produces a stable or chemically feasible compound, such as a compound that will not spontaneously transform by rearrangement, cyclization, elimination, etc. Unless otherwise specified, the "optionally substituted" group can have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted by more than one substituent selected from a specified group, the substituent can be the same or different at each position. It should be understood by those skilled in the art that the substituent itself can be substituted when appropriate. Unless specifically stated as "unsubstituted", reference to the chemical part herein should be understood to include substituted variants. For example, reference to "aryl" or "aryl" moieties implicitly includes both substituted and unsubstituted variants.

[0091] Compound

[0092] The present disclosure provides novel compounds of formula (I) and pharmaceutically acceptable salts thereof, synthetic methods for making the compounds, pharmaceutical compositions containing the same, and various uses of the disclosed compounds.

[0093] In one aspect, the present disclosure provides a compound having formula (I'):

[0094]

[0095] or a pharmaceutically acceptable salt thereof,

[0096] in

[0097] R 1 and R 2 are each independently hydrogen, halogen or alkyl, the alkyl being optionally substituted by one or more groups independently selected from halogen, hydroxy, cyano, amino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, or

[0098] R 1 and R 2 Together with the carbon atom to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl;

[0099] Optionally one or more R a replace;

[0100] Each R ais selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl, alkynyl or haloalkyl, or

[0101] Two R's a together with the carbon atom to which they are attached, form a cycloalkyl or heterocyclyl group, which may be optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl;

[0102] L is selected from *-L 1 -or*-L 2 -(CH2) q -L 3 -,

[0103] L 1 and L 2 Each independently selected from the group consisting of: a bond, *-N(R b )-, *-O-, *-S-, *-CR b =CR c -,*-C≡C-,*-S(O)-,*-SO2-, *-ZC(O)-Z- and The * end of L is The * end connection;

[0104] L 3 Selected from bonds, -N(R b )-、-O-、-S-、-CR b =CR c -, -C≡C-, -S(O)- or -SO2-,

[0105] Each V is independently selected from CR b or N, each Z is independently selected from a bond, -CR b R c -, -O- or -N(R b )-;

[0106] R b and R c are each independently selected from hydrogen, halogen, alkyl or haloalkyl;

[0107] Ring A is a 5-membered or 6-membered heterocyclic group;

[0108] Each R 3 is independently hydrogen, halogen or alkyl, the alkyl being optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino, alkenyl or alkynyl, or

[0109] One or two pairs of R 3each together with the carbon atom to which they are attached form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl or alkynyl;

[0110] R 4 It is a warhead that can covalently bind to 3CL protease;

[0111] G is C or Si;

[0112] R 5A , R 5B and R 6 are each independently selected from hydrogen, halogen, -OR d , alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl or alkylheteroaryl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocyclyl, alkylaryl and alkylheteroaryl are optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy or haloalkyl, and R d is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkylaryl, alkylcycloalkyl, alkylheterocyclyl, alkylheteroaryl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or

[0113] R 5A and R 5B Together with the G atom to which they are attached, they form a cycloalkyl or heterocyclyl group, wherein the cycloalkyl and heterocyclyl groups are optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl; or

[0114] R 5B and R 6 together with the atoms to which they are attached form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl;

[0115] R 7 For-R 7-1 -R 7-2 , where R 7-1 Selected from a bond, -C(O)O-**, -C(O)-**, -C(O)N(R b )-** or -SO2-**, R 7-2is selected from hydrogen, halogen, alkyl, haloalkyl, alkoxy, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, alkenylcycloalkyl, alkenylheterocyclyl, alkenylaryl, alkenylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said alkyl, alkoxy, alkylcycloalkyl, alkylheterocyclyl, alkylaryl, alkylheteroaryl, alkenylcycloalkyl, alkenylheterocyclyl, alkenylaryl, alkenylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy, haloalkyl or -C(O)CF3, wherein R 7-1 The ** end is connected to R 7-2 ;

[0116] R 8 is selected from hydrogen, halogen, alkyl or haloalkyl; or

[0117] R 7 and R 8 Together with the nitrogen atom to which they are attached, they form a heterocyclic group, which is optionally substituted by one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl;

[0118] R 9 is selected from hydrogen, methyl or ethyl;

[0119] m is 0, 1, 2, 3, or 4;

[0120] n is 0, 1, 2, 3, or 4;

[0121] p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; and

[0122] q is 0, 1, or 2.

[0123] In another aspect, a compound having formula (I) or (II) is provided:

[0124]

[0125] or a pharmaceutically acceptable salt thereof, wherein L, R 1 -R 4 , R 5A , R 5B , R 6 , R 7 , m, n and p are as defined above.

[0126] In some embodiments, R 1 and R 2 Each is independently hydrogen, halogen or alkyl.

[0127] In some embodiments, R1 and R 2 All are hydrogen.

[0128] In some embodiments, R 1 and R 2 In certain embodiments, R 1 and R 2 All are methyl.

[0129] In some embodiments, R 1 and R 2 are each independently hydrogen or halogen.

[0130] In some embodiments, R 1 and R 2 In certain embodiments, one of R is hydrogen and the other is halogen. 1 and R 2 One of them is hydrogen and the other is fluorine.

[0131] In some embodiments, R 1 and R 2 Together with the carbon atom to which they are attached they form a cycloalkyl group which is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl.

[0132] In certain embodiments, R 1 and R 2 Together with the carbon atom to which they are attached they form a cyclopropyl group which is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl.

[0133] In some embodiments, Optionally one or more R a Replace, and each R a is independently selected from halogen, alkyl or haloalkyl. a is independently fluoro, methyl, ethyl, propyl or trifluoromethyl.

[0134] In some embodiments, R is optionally substituted with one or more R, and two R together with the carbon atom to which they are attached form a cycloalkyl group, which is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl. a Together with the carbon atom to which they are attached they form a cyclopropyl group which is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl.

[0135] In some embodiments, L is *-L1 -, and L 1 is the key.

[0136] In certain embodiments, Selected from

[0137] In some embodiments, L is *-L 1 -, and L 1 *-N(R b )-. In certain embodiments, R b is selected from hydrogen, halogen, alkyl or haloalkyl. b is selected from hydrogen, fluorine, methyl or trifluoromethyl.

[0138] In certain embodiments, Select from the following group:

[0139]

[0140] In some embodiments, L is *-L 1 -, and L 1 It is *-O-.

[0141] In certain embodiments, Select from the following group:

[0142]

[0143] In some embodiments, L is *-L 1 -, and L 1 It is *-S-.

[0144] In certain embodiments, Selected from

[0145] In some embodiments, L is *-L 1 -, and L 1 For *-CR b =CR c -. In certain embodiments, R b and R c Each is independently hydrogen or alkyl. b and R c Each is independently hydrogen or methyl. In certain embodiments, R b and R c In certain embodiments, R b and R c In certain embodiments, R band R c One of them is hydrogen and the other is methyl.

[0146] In certain embodiments, Select from the following group:

[0147]

[0148]

[0149] A wavy line directly connected to a double bond indicates that the double bond is in the E or Z configuration.

[0150] In some embodiments, L is *-L 2 -(CH2) q -L 3 -, where L 2 *-O-, L 3 For-CR b =CR c -.

[0151] In certain embodiments, Selected from

[0152] In some embodiments, L is *-L 2 -(CH2) q -L 3 -, where L 2 For *-CR b =CR c -, and L 3 It is -O-.

[0153] In certain embodiments, Selected from

[0154] In some embodiments, L is *-L 1 -, and L 1 *-C≡C-.

[0155] In certain embodiments, Selected from

[0156] In some embodiments, L is *-L 1 -, and L 1 It is *-S(O)-.

[0157] In certain embodiments, Selected from

[0158] In some embodiments, L is *-L 1 -, and L 1 It is *-SO2-.

[0159] In certain embodiments, Selected from

[0160] In some embodiments, L is *-L 1 -, and L 1 for In certain embodiments, Z is -CR b R c -, -O- or -N(R b )-, where R b and R c Each is independently hydrogen or alkyl.

[0161] In certain embodiments, Selected from

[0162] In some embodiments, L is *-L 1 -, and L 1 In certain embodiments, Z is -CR b R c -, -O- or -N(R b )-, where R b and R c Each is independently hydrogen, alkyl or haloalkyl. b and R c Each is independently hydrogen, methyl or trifluoromethyl.

[0163] In certain embodiments, Select from the following group:

[0164]

[0165]

[0166] In some embodiments, Select from the following group:

[0167]

[0168] In some embodiments, Ring A is selected from wherein X, Y, W and T are each independently selected from -C-, -N- or -O-, and wherein Each of optionally contains a double bond.

[0169] In some embodiments, each R 3 is independently hydrogen, halogen or alkyl, the alkyl being optionally substituted with one or more groups independently selected from halogen.

[0170] In some embodiments, one or two pairs of R 3 Each together with the carbon atom to which they are attached forms a cycloalkyl or aryl group, wherein the cycloalkyl and aryl groups are optionally substituted with one or more groups independently selected from halogen or alkyl.

[0171] In some embodiments, Ring A is selected from the group consisting of

[0172]

[0173] In certain embodiments, each R 3 is independently hydrogen, halogen or alkyl, the alkyl being optionally substituted with one or more groups independently selected from halogen, hydroxyl or cyano.

[0174] In certain embodiments, a pair of R 3 Together with the carbon atom to which they are attached they form a cycloalkyl group which is optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano or alkyl.

[0175] In some embodiments, Ring A is selected from the group consisting of:

[0176]

[0177]

[0178] In some embodiments, Ring A is selected from the group consisting of

[0179]

[0180] In certain embodiments, each R 3 is independently hydrogen, halogen or alkyl, the alkyl being optionally substituted with one or more groups independently selected from halogen, hydroxyl or cyano.

[0181] In certain embodiments, one or two pairs of R 3 Each together with the carbon atom to which they are attached forms a cycloalkyl or aryl group, wherein the cycloalkyl and aryl groups are optionally substituted with one or more groups independently selected from halogen or alkyl.

[0182] In some embodiments, Ring A is selected from the group consisting of

[0183]

[0184]

[0185] In some embodiments, Ring A is selected from the group consisting of

[0186] In some embodiments, Ring A is selected from the group consisting of

[0187] In some embodiments, Ring A is selected from the group consisting of

[0188] In some embodiments, Ring A is selected from the group consisting of

[0189] In some embodiments, Ring A is selected from the group consisting of

[0190] In some embodiments, Ring A is selected from the group consisting of

[0191] In some embodiments, Ring A is selected from the group consisting of

[0192] In some embodiments, Ring A is selected from the group consisting of

[0193] In some embodiments, Ring A is selected from the group consisting of

[0194] In some embodiments, Ring A is selected from the group consisting of

[0195] In some embodiments, Ring A is selected from the group consisting of

[0196]

[0197] In some embodiments, Ring A is selected from the group consisting of

[0198]

[0199] In some embodiments, Ring A is selected from the group consisting of

[0200] In some embodiments, Ring A is selected from the group consisting of

[0201] In some embodiments, Ring A is selected from the group consisting of

[0202] In some embodiments, Ring A is selected from the group consisting of

[0203] In some embodiments, R 4 Select from the following group:

[0204]

[0205]

[0206] In some embodiments, R 5A , R 5B and R 6 are each independently selected from hydrogen, -OR d , alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, wherein the cycloalkyl, aryl, heteroaryl, alkylaryl and alkylheteroaryl are optionally substituted with one or more groups independently selected from halogen, alkyl or haloalkyl.

[0207] In certain embodiments, Select from the following group:

[0208]

[0209]

[0210]

[0211] In some embodiments, R 5A and R 5B Together with the G atom to which they are attached they form a cycloalkyl or heterocyclyl, wherein said cycloalkyl or heterocyclyl is optionally substituted by one or more groups independently selected from halogen or alkyl.

[0212] In certain embodiments, G is C, and Select from the following group:

[0213]

[0214] In certain embodiments, G is Si, and Select from the following group:

[0215]

[0216] In some embodiments, R 5A is hydrogen, and R 5B and R 6 Together with the atoms to which they are attached they form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more groups independently selected from halogen or alkyl.

[0217] In certain embodiments, Select from the following group:

[0218]

[0219]

[0220] In some embodiments, R 7 For –R 7-1 -R 7-2 , R 7-1 is a key, and R 7-2 is selected from alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, alkyl, alkoxy or haloalkyl.

[0221] In certain embodiments, R 7-2 Selected from

[0222] -CH3, -CH2CH3, -CF2CF3 and -CH2CF3.

[0223] In some embodiments, R 7-1 is -C(O)O-**, and R 7-2 is selected from alkyl, haloalkyl, alkylcycloalkyl, alkylaryl, cycloalkyl, aryl or heteroaryl, wherein the alkyl, alkylcycloalkyl, alkylaryl and cycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, hydroxy, cyano, alkyl, alkoxy or haloalkyl.

[0224] In certain embodiments, R 7 Select from the following group:

[0225]

[0226]

[0227] In some embodiments, R7 For –R 7-1 -R 7-2 , R 7-1 -C(O)-**, R 7-2 is selected from alkyl, haloalkyl, alkylcycloalkyl, alkylaryl, alkenylaryl, heteroalkylcycloalkyl, heteroalkylaryl, heteroalkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkylaryl, alkenylaryl, heteroalkylaryl, heteroalkylheteroaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more groups independently selected from halogen, hydroxy, carbonyl, alkyl, alkoxy or haloalkyl.

[0228] In certain embodiments, R 7 Select from the following group:

[0229]

[0230] In some embodiments, R 7 For –R 7-1 -R 7-2 , R 7-1 -C(O)N(R b )-**, R 7-2 is selected from alkyl, haloalkyl, alkylcycloalkyl, alkylaryl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkylcycloalkyl, alkylaryl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, alkyl, alkoxy or haloalkyl.

[0231] In certain embodiments, R 7 Select from the following group:

[0232]

[0233] In some embodiments, R 7 For –R 7-1 -R 7-2 , R 7-1 is -SO2-**, and R 7-2 is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, alkyl, alkoxy or haloalkyl.

[0234] In certain embodiments, R 7 Select from the following group:

[0235]

[0236] In some embodiments, R 7 For –R 7-1-R 7-2 , R 7-1 is a key, and R 7-2 For hydrogen.

[0237] In certain embodiments, R 7 is -NH2.

[0238] In some embodiments, R 7 and R 8 Together with the nitrogen atom to which they are attached they form a heterocyclic group which is optionally substituted by one or more groups independently selected from halogen, hydroxy, cyano, amino or alkyl.

[0239] In certain embodiments, R 7 and R 8 The heterocyclic radicals formed together with the nitrogen atom to which they are attached are selected from the group consisting of:

[0240]

[0241] In some embodiments, the present disclosure provides compounds of formula (III):

[0242]

[0243] or a pharmaceutically acceptable salt thereof, wherein L, G, R 5A , R 5B , R 6 , R 7 , m and n are as defined above.

[0244] In some embodiments, the present disclosure provides compounds of formula (IIIa) or (IIIb):

[0245]

[0246] or a pharmaceutically acceptable salt thereof, wherein L, R 5A , R 5B , R 6 , R 7 , m and n are as defined above.

[0247] In some embodiments, the present disclosure provides compounds of Formula (Ia):

[0248]

[0249] or a pharmaceutically acceptable salt thereof.

[0250] In some embodiments, the present disclosure provides compounds of formula (Ia'):

[0251]

[0252] or a pharmaceutically acceptable salt thereof.

[0253] In yet another aspect, the present disclosure provides a compound having a chemical formula selected from the group consisting of:

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271]

[0272]

[0273] or a pharmaceutically acceptable salt thereof, wherein a wavy line directly attached to a double bond indicates that the double bond is in the E or Z configuration.

[0274] The compounds provided herein are described with reference to general chemical formulae and specific compounds. In addition, the disclosed compounds may exist in many different forms or derivatives, all of which are within the scope of the present disclosure. These include, for example, tautomers, stereoisomers, racemic mixtures, regioisomers, salts, solvated forms, amorphous forms, different crystalline forms or polymorphs.

[0275] Depending on the substituent selection, the disclosed compounds may include one or more asymmetric centers, and therefore may exist in various stereoisomeric forms, such as enantiomers and / or diastereomers. For example, the compounds provided herein may have an asymmetric carbon center, and therefore the compounds provided herein may have (R) or (S) stereo configuration at the carbon asymmetric center. Therefore, the disclosed compounds may be in the form of individual enantiomers, diastereomers or geometric isomers, or may be in the form of a mixture of stereoisomers.

[0276] As used herein, the term "enantiomer" refers to two stereoisomers of a compound that are non-superimposable mirror images of each other. The term "diastereomer" refers to a pair of optical isomers that are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity.

[0277] When a particular enantiomer is preferred, it may be provided in some embodiments as being substantially free of the relative enantiomer, and may also be referred to as "optically enriched". As used herein, "optically enriched" means that the compound is composed of a significantly larger proportion of one enantiomer. In certain embodiments, the compound is composed of at least about 90% by weight of the preferred enantiomer. In other embodiments, the compound is composed of at least about 95%, 98% by weight, or 99% by weight of the preferred enantiomer. The preferred enantiomer may be separated from the racemic mixture by any method known to those skilled in the art, such as by chromatography or crystallization, by synthesizing using stereochemically uniform starting materials, or by stereoselective synthesis. Optionally, derivatization may be performed before separating stereoisomers. The separation of a mixture of stereoisomers may be performed during the synthesis of the compounds provided herein at an intermediate step or it may be performed on the final racemic product. Absolute stereochemistry may be determined by X-ray crystallography of a crystalline product or a crystalline intermediate, which may be derivatized with a reagent containing a stereocenter of a known configuration if necessary. Alternatively, absolute stereochemistry can be determined by vibrational circular dichroism (VCD) spectroscopy. See, e.g., Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, SH et al., Tetrahedron 33:2725 (1977); Eliel, EL Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH Tables of Resolving Agents and Optical Resolutions, p. 268 (ELEiel, ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

[0278] In some embodiments, a mixture of diastereomers is provided, for example, a mixture of diastereomers enriched with 51% or more of one of the diastereomers, including, for example, 60% or more, 70% or more, 80% or more, or 90% or more of one of the diastereomers.

[0279] In some embodiments, unless otherwise indicated, the compounds provided herein may have one or more double bonds that exist as Z or E isomers. In addition, the disclosure also encompasses compounds in the form of individual isomers that are substantially free of other isomers, and alternatively, in the form of mixtures of multiple isomers (e.g., racemic mixtures of enantiomers).

[0280] The disclosed compounds can also exist in different tautomeric forms, and all such forms are included in the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can be mutually converted via low energy barriers. For example, proton tautomers (also referred to as prototransfer tautomers) include mutual conversions via proton migration, such as keto-enols, amide-imidic acids, lactams-lactams, imine-enamine isomerizations and cyclic forms, wherein protons can occupy two or more positions of heterocyclic systems (e.g., 1H-imidazoles and 3H-imidazoles, 1H-1,2,4-triazoles, 2H-1,2,4-triazoles and 4H-1,2,4-triazoles, 1H-isoindoles and 2H-isoindoles and 1H-pyrazoles and 2H-pyrazoles). Valence tautomers include mutual conversions performed by rearrangement of some bonding electrons. Tautomers can be in equilibrium or spatially locked into a form by appropriate substitution. Unless otherwise specified, a compound of the disclosure identified by name or structure as a particular tautomeric form is intended to encompass the other tautomeric forms.

[0281] The present disclosure is also intended to include all isotopes of atoms in the compounds. Isotopes of atoms include atoms having the same atomic number but different mass numbers. For example, unless otherwise specified, hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, or iodine in the compounds of the present disclosure is also intended to include its isotopes, such as (but not limited to) 1 H. 2 H. 3 H. 11 C. 12 C. 13 C. 14 C. 14 N. 15 N. 16 O. 17 O. 18 O. 31 P. 32 P. 32 S. 33 S. 34 S. 36 S. 17 F. 18 F. 19 F. 35 Cl, 37 Cl, 79Br, 81 Br, 124 I. 127 I and 131 1. In some embodiments, hydrogen comprises protium, deuterium, and tritium. In some embodiments, carbon comprises 12 C and 13 C. Isotopically enriched compounds of formula (I) may be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein, using appropriate isotopically enriched reagents and / or intermediates.

[0282] The compounds of the present disclosure may be formulated as or in the form of pharmaceutically acceptable salts. Unless specified to the contrary, the compounds provided herein include pharmaceutically acceptable salts of such compounds.

[0283] As used herein, the term "pharmaceutically acceptable" indicates that the substance or composition described is chemically and / or toxicologically compatible with the other ingredients making up the formulation and / or the individual being treated therewith.

[0284] As used herein, unless otherwise indicated, the term "pharmaceutically acceptable salt" includes salts that retain the biological effectiveness of the free acids and bases of the specified compound and are not biologically or otherwise undesirable. Pharmaceutically acceptable salt forms contemplated include, but are not limited to, monosalts, disalts, trisalts, tetrasalts, and the like. Pharmaceutically acceptable salts are nontoxic in the amounts and concentrations to which they are applied. The preparation of such salts can facilitate pharmacological use by changing the physical characteristics of the compound without preventing it from exerting its physiological effects. Useful changes in physical properties include lowering the melting point to facilitate transmucosal administration and increasing solubility to facilitate administration of higher concentrations of the drug.

[0285] Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, chloride, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamate, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamate, fumaric acid and quinic acid.

[0286] When an acidic functional group (such as carboxylic acid or phenol) is present, pharmaceutically acceptable salts also include base addition salts, such as those containing the following: benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, tert-butylamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamines and zinc. See, for example, Remington's Pharmaceutical Sciences, 19th edition, Mack Publishing Co., Easton, PA, Vol. 2, p. 1457, 1995; Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Weinheim, Germany, 2002. Such salts can be prepared using the appropriate corresponding bases.

[0287] Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free base form of the compound can be dissolved in a suitable solvent (such as an aqueous solution or water-alcohol solution containing a suitable acid), and then separated by evaporating the solution. Therefore, if the specific compound is a base, the desired pharmaceutically acceptable salt can be prepared by any suitable method available in the art, for example, with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. to treat the free base, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosyl acid (such as glucuronic acid or galacturonic acid), alpha-hydroxy acid (such as citric acid or tartaric acid), amino acid (such as aspartic acid or glutamic acid), aromatic acid (such as benzoic acid or cinnamic acid), sulfonic acid (such as p-toluenesulfonic acid or ethanesulfonic acid), etc. to treat the free base.

[0288] Similarly, if the particular compound is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, by treating the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or an alkaline earth metal hydroxide, etc. Illustrative examples of suitable salts include organic salts derived from amino acids (such as L-glycine, L-lysine and L-arginine), ammonia, primary, secondary and tertiary amines and cyclic amines, such as hydroxyethylpyrrolidine, piperidine, morpholine or piperazine; and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.

[0289] It will also be understood that the compounds of the disclosure may exist in unsolvated forms, solvated forms (eg, hydrated forms), and solid forms (eg, crystalline or polymorphic forms), and that the disclosure is intended to encompass all such forms.

[0290] As used herein, the term "solvate" or "solvated form" refers to a solvent addition form containing a stoichiometric or non-stoichiometric amount of a solvent. Some compounds have a tendency to entrap a fixed molar ratio of solvent molecules in a crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate; and if the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more water molecules with a molecule of a substance, wherein the water retains its molecular state as H2O. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

[0291] As used herein, the terms "crystal form", "crystalline form", "polymorphic form" and "polymorph" are used interchangeably and refer to crystal structures in which a compound (or its salt or solvate) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shapes, optical and electrical properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors can make one crystal form dominant. Crystalline polymorphs of a compound can be prepared by crystallization under different conditions.

[0292] The present disclosure is also intended to include all isotopes of atoms in the compounds. Isotopes of atoms include atoms having the same atomic number but different mass numbers. For example, unless otherwise specified, hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, or iodine in the compounds of the present disclosure is also intended to include its isotopes, such as (but not limited to) 1 H. 2 H. 3 H. 11 C. 12 C. 13 C. 14 C. 14 N. 15 N. 16 O. 17 O. 18 O. 31 P. 32 P. 32 S. 33 S. 34 S. 36 S. 17 F. 18 F.19 F. 35 Cl, 37 Cl, 79 Br, 81 Br, 124 I. 127 I and 131 1. In some embodiments, hydrogen comprises protium, deuterium, and tritium. In some embodiments, carbon comprises 12 C and 13 C.

[0293] Synthesis of compounds

[0294] The synthesis of the compound (including its pharmaceutically acceptable salt) provided herein is described in the synthesis scheme in the example. The compound provided herein can be prepared using any known organic synthesis technology and can be synthesized according to any of a variety of possible synthetic pathways, and therefore, these schemes are only illustrative and are not intended to limit other possible methods that can be used to prepare the compound provided herein. In addition, the steps in the scheme are to better illustrate and can be changed when appropriate. For the purpose of research and possible submission to the regulatory agency, the embodiment of the compound in the example is synthesized.

[0295] The reaction for preparing the disclosed compounds can be carried out in a suitable solvent, which can be easily selected by a technician in the field of organic synthesis. Suitable solvents can be at a temperature where the reaction is carried out, for example, at a temperature within the range of the freezing temperature of the solvent to the boiling temperature of the solvent, substantially not reacting with the starting material (reactant), intermediate or product. The specified reaction can be carried out in a solvent or a mixture of more than one solvent. Depending on the specific reaction step, the suitable solvent for the specific reaction step can be selected by a technician in the field.

[0296] The preparation of the disclosed compounds may involve the protection and deprotection of various chemical groups. The demand for protection and deprotection, and the selection of appropriate protecting groups can be easily determined by those skilled in the art. The chemical properties of protecting groups can be found in, for example, TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis", 3rd edition, Wiley & Sons, Inc., New York (1999); P. Kocienski, "Protective Groups", Georg Thieme Verlag, 2003; and Peter G. M. Wuts, "Greene's Protective Groups in Organic Synthesis", 5th edition, Wiley, 2014, all of which are incorporated herein by reference in their entirety.

[0297] The reaction can be monitored by any suitable method known in the art. For example, the reaction can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g. 1 H or 13 C), infrared spectroscopy (IR), spectrophotometry (e.g., UV-visible light), mass spectrometry, or by chromatography, such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LCMS) or thin layer chromatography (TLC) to monitor product formation. Those skilled in the art can purify compounds by a variety of methods, including high performance liquid chromatography (HPLC) ("Preparative LC-MS Purification: Improved Compound Specific Method Optimization", Karl F. Blom, Brian Glass, Richard Sparks, Andrew P. Combs, "Journal of Combinatorial Chemistry (J. Combi. Chem.)", 2004, 6 (6), 874-883, which is incorporated herein by reference in its entirety) and normal phase silica chromatography.

[0298] Known starting materials of the present disclosure can be synthesized by using or according to methods known in the art, or can be purchased from commercial suppliers. Unless otherwise noted, analytical grade solvents and commercially available reagents were used without further purification.

[0299] Unless otherwise specified, the reactions of the present disclosure were carried out under a positive pressure of nitrogen or argon or in anhydrous solvents with dried tubes, and the reaction flasks were usually equipped with rubber septa for the introduction of substrates and reagents via syringes. Glassware was oven-dried and / or heat-dried.

[0300] For illustrative purposes, the following examples partially show synthetic routes and key intermediates for preparing compounds of the present disclosure. It will be appreciated by those skilled in the art that other synthetic routes can be used to synthesize the compounds of the present invention. Although specific starting materials and reagents are described, other starting materials and reagents can be easily replaced to provide a variety of derivatives and / or reaction conditions. In addition, many compounds prepared by the methods described below can be further adjusted according to the present disclosure using conventional chemical reactions known to those skilled in the art.

[0301] Uses of Compounds

[0302] In one aspect, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is capable of inhibiting 3CL. Therefore, the compounds of the present disclosure or pharmaceutically acceptable salts thereof can be used as drugs, and in particular can be used as therapeutic agents or preventive agents active against various viruses. In some embodiments, the compounds of the present disclosure are therapeutic agents or preventive agents active against caliciviruses, picornaviruses, and coronaviruses.

[0303] As used herein, the term "therapy" is intended to have its ordinary meaning, i.e., to treat a disease so as to completely or partially relieve one, some or all of its symptoms, or to correct or counteract the underlying pathology, thereby achieving a beneficial or desired clinical outcome. For the purposes of this disclosure, beneficial or desired clinical outcomes include, but are not limited to, relief of symptoms, alleviation of the extent of the disease, stabilization of the disease state (i.e., no deterioration), delay or slowing of disease progression, improvement or alleviation of the disease condition, and relief (partial or complete relief), whether detectable or undetectable. "Therapy" may also mean an extension of survival compared to the expected survival without therapy. Situations requiring therapy include situations in which a condition or illness has been suffered, as well as situations in which a condition or illness is prone to be suffered, or in order to prevent a condition or illness. Unless there is a specific indication to the contrary, the term "therapy" also encompasses prevention. The terms "therapeutic" and "therapeutically" should be interpreted in a corresponding manner.

[0304] The term "treat" is used synonymously with "therapy." Similarly, the term "treatment" can be viewed as "administering therapy," where "therapy" is as defined herein.

[0305] As used herein, the term "prevention" is intended to have its ordinary meaning and includes primary prevention, which is used to prevent the development of a disease, and secondary prevention, which temporarily or permanently protects a patient from exacerbating or worsening the disease or developing new symptoms associated with the disease once the disease has developed.

[0306] In yet another aspect, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof for treating a viral infection.

[0307] In yet another aspect, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present disclosure in the preparation of a medicament for treating viral infection.

[0308] In another aspect, it is surprisingly found that the compounds provided herein show high resistance to oxidative enzymes. This allows the compounds provided herein to resist oxidative metabolism in vivo, thereby showing greater metabolic stability, such as increased half-life in vivo or reduced dosage requirements.

[0309] In some embodiments, the compounds provided herein can be administered to a subject in need thereof without the need for co-administration of an oxidase inhibitor, such as ritonavir or cobicistat.

[0310] Pharmaceutical composition

[0311] For administration purposes, in some embodiments, the compounds provided herein are administered as the raw chemical substance or formulated into a pharmaceutical composition.

[0312] Thus, in another aspect, provided are pharmaceutical compositions comprising one or more compounds of the present disclosure, or pharmaceutically acceptable salts thereof.

[0313] In some embodiments, the pharmaceutical composition of the present disclosure comprises a compound selected from any one of formulas (I) to (VII) or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition of the present disclosure comprises a first compound selected from any one of formulas (I) to (VII) or a pharmaceutically acceptable salt thereof and one or more additional compounds of the same formula, but the first compound and the additional compound are not the same molecule.

[0314] As used herein, the term "pharmaceutical composition" refers to a formulation containing a molecule or compound of the disclosure in a form suitable for administration to a subject.

[0315] In some embodiments, the pharmaceutical compositions of the present disclosure comprise a therapeutically effective amount of one or more compounds of Formula (I) to (VII) or a pharmaceutically acceptable salt thereof.

[0316] As used herein, the term "therapeutically effective amount" refers to the amount of a molecule, compound, or composition comprising the molecule or compound that treats, ameliorates, or prevents an identified disease or condition, or shows a detectable therapeutic or inhibitory effect. The effect can be detected by any analytical method known in the art. The precise effective amount for an individual will depend on the individual's weight, stature, and health; the nature and extent of the condition; the rate of administration; the therapeutic agent or combination of therapeutic agents selected for administration; and the judgment of the prescribing physician. The therapeutically effective amount for a given situation can be determined by routine experiments within the skill and judgment of the clinician.

[0317] In another aspect, provided are pharmaceutical compositions comprising one or more molecules or compounds of the present disclosure, or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient.

[0318] As used herein, the term "pharmaceutically acceptable excipient" refers to an excipient suitable for preparing a pharmaceutical composition that is generally safe, non-toxic, and biologically and otherwise desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. As used herein, "pharmaceutically acceptable excipient" includes one and more than one such excipient. The term "pharmaceutically acceptable excipient" also encompasses "pharmaceutically acceptable carriers" and "pharmaceutically acceptable diluents".

[0319] The specific excipient used will depend on the means and purpose for which the disclosed compounds are to be administered. The solvent is generally selected based on a solvent recognized as safe by those skilled in the art to be administered to a mammal (including a human). In general, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG 400, PEG 300), etc. and mixtures thereof.

[0320] In some embodiments, suitable excipients may include buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; chloride); phenol, butyl alcohol or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, dextrin or substituted dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (such as Zn-protein complexes); and / or nonionic surfactants such as TWEEN®. TM 、PLURONICS TM or polyethylene glycol (PEG).

[0321] In some embodiments, suitable excipients may include one or more stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, slip agents, processing aids, colorants, sweeteners, aromatics, flavoring agents and other known additives to provide the best presentation of drugs (i.e., compounds disclosed herein or their pharmaceutical compositions) or to help manufacture pharmaceutical products (i.e., medicaments). Active pharmaceutical ingredients may also be coated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as hydroxymethylcellulose or gelatin microcapsules and poly (methyl methacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in coarse emulsions, respectively. Such technology is disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A., ed. (1980). "Liposomes" are vesicles comprising various types of lipids, phospholipids and / or surfactants, which are suitable for delivering drugs (compounds disclosed herein and optional chemotherapeutic agents) to mammals (including humans). The components of liposomes are typically arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

[0322] The pharmaceutical compositions provided herein may be in any form that permits administration of the composition to an individual, including but not limited to humans, and is formulated to be compatible with the intended route of administration.

[0323] Multiple approaches are considered for the pharmaceutical composition provided herein, and therefore the pharmaceutical composition provided herein can be supplied in bulk or unit dosage form depending on the expected route of administration. For example, for oral, buccal and sublingual administration, powders, suspensions, granules, lozenges, pills, capsules, soft capsules and caplets are acceptable as solid dosage forms, and emulsions, syrups, elixirs, suspensions and solutions are acceptable as liquid dosage forms. For injection administration, emulsions and suspensions are acceptable as liquid dosage forms, and powders suitable for reconstitution with suitable solutions are acceptable as solid dosage forms. For inhalation administration, solutions, sprays, dry powders and aerosols can be acceptable dosage forms. For topical (including buccal and sublingual) or transdermal administration, powders, sprays, ointments, pastes, creams, lotions, gels, solutions and patches can be acceptable dosage forms. For vaginal administration, vaginal suppositories, tampons, creams, gels, pastes, foams and sprays can be acceptable dosage forms.

[0324] The amount of active ingredient in the unit dosage form of the composition is a therapeutically effective amount and varies according to the specific treatment involved. As used herein, the term "therapeutically effective amount" refers to the amount of a molecule, compound, or composition comprising the molecule or compound that treats, improves, or prevents an identified disease or condition or shows a detectable therapeutic or inhibitory effect. The effect can be detected by any analytical method known in the art. The precise effective amount for an individual will depend on the individual's weight, stature, and health; the nature and extent of the condition; the rate of administration; the therapeutic agent or combination of therapeutic agents selected for administration; and the judgment of the prescribing physician. The therapeutically effective amount for a given situation can be determined by routine experiments within the skill and judgment of the clinician.

[0325] In some embodiments, the pharmaceutical compositions of the present disclosure may be in the form of oral administration formulations.

[0326] In certain embodiments, the pharmaceutical compositions of the present disclosure may be in the form of tablet formulations. Pharmaceutically acceptable excipients suitable for tablet formulations include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate; granulating agents and disintegrants such as corn starch or alginic acid; binders such as starch; lubricants such as magnesium stearate, stearic acid or talc; preservatives such as ethyl paraben or propyl paraben; and antioxidants such as ascorbic acid. Tablet formulations may be uncoated or coated with coatings to regulate their disintegration and subsequent absorption of active ingredients in the gastrointestinal tract, or to improve their stability and / or appearance, in either case, conventional coating agents and procedures well known in the art are used.

[0327] In certain embodiments, the pharmaceutical compositions of the present disclosure may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., calcium carbonate, calcium phosphate, or kaolin); or in the form of soft gelatin capsules in which the active ingredient is mixed with water or oil (e.g., peanut oil, liquid paraffin, or olive oil).

[0328] In certain embodiments, the pharmaceutical compositions of the present disclosure may be in the form of an aqueous suspension, which generally contains the active ingredient in fine powder form and one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum arabic; a dispersant or wetting agent, such as lecithin, or a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), or a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxyhexadecanoic acid), or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitan monooleate), or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives (for example, ethyl or propyl p-hydroxybenzoate), antioxidants (for example, ascorbic acid), coloring agents, flavoring agents and / or sweetening agents (for example, sucrose, saccharin or aspartame).

[0329] In certain embodiments, the pharmaceutical composition of the present disclosure can be in the form of an oily suspension, which generally contains a suspended active ingredient in a vegetable oil (such as peanut oil, castor oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspension can also contain a thickener, such as beeswax, hard paraffin or cetyl alcohol. Sweeteners (such as those stated above) and flavoring agents can be added to provide a palatable oral formulation. These compositions can be preserved by adding an antioxidant (such as ascorbic acid).

[0330] In certain embodiments, the pharmaceutical composition of the present disclosure may be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil, such as olive oil or peanut oil; or a mineral oil, such as liquid paraffin; or a mixture of any of these oils. Suitable emulsifiers may be, for example, naturally occurring gums, such as gum arabic or gum tragacanth; naturally occurring phospholipids, such as soybeans, lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides (e.g., sorbitan monooleate), and condensation products of the partial esters with ethylene oxide (e.g., polyoxyethylene sorbitan monooleate). The emulsion may also contain sweeteners, flavorings, and preservatives.

[0331] In certain embodiments, the pharmaceutical compositions provided herein may be in the form of syrups and elixirs, which may contain sweeteners, such as glycerol, propylene glycol, sorbitol, aspartame or sucrose; demulcents; preservatives; flavoring and / or coloring agents.

[0332] In some embodiments, the pharmaceutical compositions of the present disclosure may be in the form of formulations for injectable administration.

[0333] In certain embodiments, the pharmaceutical composition of the present disclosure can be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oily suspension. This suspension can be prepared according to known techniques using those suitable dispersants or wetting agents and suspending agents mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol or prepared as a lyophilized powder. The acceptable vehicles and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils can be used as solvents or suspension media conventionally. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid can also be used to prepare injectables.

[0334] In some embodiments, the pharmaceutical compositions of the present disclosure may be in the form of an inhaled administration formulation.

[0335] In certain embodiments, the pharmaceutical compositions of the present disclosure may be in the form of aqueous and non-aqueous (e.g., in fluorocarbon propellants) aerosols containing any suitable solvent and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH adjusters, surfactants, bioavailability modifiers, and combinations of these. Carriers and stabilizers vary with the requirements of a particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins (such as serum albumin), sorbitan esters, oleic acid, lecithin, amino acids (such as glycine), buffers, salts, sugars, or sugar alcohols.

[0336] In some embodiments, the pharmaceutical compositions of the present disclosure may be in the form of formulations for topical or transdermal administration.

[0337] In certain embodiments, the pharmaceutical compositions provided herein may be in the form of creams, ointments, gels, and aqueous or oily solutions or suspensions, which can generally be obtained by formulating the active ingredient with conventional topically acceptable excipients, such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0338] In certain embodiments, the pharmaceutical compositions provided herein may be formulated in the form of transdermal skin patches well known to those of ordinary skill in the art.

[0339] In addition to those representative dosage forms described above, pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art, and are therefore included in the present disclosure. Such excipients and carriers are described in, for example, "Remington's Pharmaceutical Sciences" Mark Publishing Company, New Jersey (1991), "Remington: The Science and Practice of Pharmacy", University of the Sciences in Philadelphia, 21st edition, LWW (2005), which is incorporated herein by reference.

[0340] In certain embodiments, the pharmaceutical composition of the present disclosure can be formulated into a unit dosage form. The term "unit dosage form" refers to a physically discrete unit suitable for use in human individuals and other mammals in a single dose, each unit containing a predetermined amount of active substance calculated to be combined with a suitable pharmaceutical excipient to produce a desired therapeutic effect. The amount of the compound provided herein in a unit dosage form will vary according to the condition to be treated, the individual to be treated (e.g., age, body weight, and response of the individual), a specific route of administration, the actual compound administered, and its relative activity and the severity of individual symptoms.

[0341] In some embodiments, the dosage of the pharmaceutical composition of the present disclosure can be 0.001-1000 mg / kg body weight / day, for example, 0.001-1000 mg / kg body weight / day, 0.001-900 mg / kg body weight / day, 0.001-800 mg / kg body weight / day, 0.001-700 mg / kg body weight / day, 0.001-600 mg / kg body weight / day, 0.001-500 mg / kg body weight / day. day, 0.001-400 mg / kg body weight / day, 0.001-300 mg / kg body weight / day, 0.001-200 mg / kg body weight / day, 0.001-100 mg / kg body weight / day, 0.001-50 mg / kg body weight / day, 0.001-40 mg / kg body weight / day, 0.001-30 mg / kg body weight / day, 0.001-20 mg / kg body weight / day, 0.001-10 mg / kg body weight / day, 0.001-5 mg / kg body weight / day, 0.001-1 mg / kg body weight / day, 0.001-0.5 mg / kg body weight / day, 0.001-0.4 mg / kg body weight / day, 0.001-0.3 mg / kg body weight / day, 0.001-0.2 mg / kg body weight / day, 0.001-0.1 mg / kg body weight / day, 0.005-0.1 mg / kg body weight / day, 0.01 In some cases, the dosage amount below the lower limit of the aforementioned range may be more than enough, and in other cases, a larger dose can be used without causing any harmful side effects, provided that the larger dose is first divided into several small doses for use throughout the day. For additional information on routes of administration and dosing regimens, see Volume 5, Chapter 25.3 in Comprehensive Medicinal Chemistry (Corwin Hansch; Head of the Editorial Board), Pergamon Press 1990, which is specifically incorporated herein by reference.

[0342] In some embodiments, the pharmaceutical compositions of the present disclosure are formulated for oral administration. In some embodiments, the unit dose for oral administration contains one or more compounds provided herein in the following amounts: about 1 mg to about 1000 mg, for example, about 5 mg to about 1000 mg, about 10 mg to about 1000 mg, about 15 mg to about 1000 mg, about 20 mg to about 1000 mg, about 25 mg to about 1000 mg, about 30 mg to about 1000 mg, about 40 mg to about 1000 mg, about 50 mg to about 1000 mg, about 60 mg to about 1000 mg, about 70 mg to about 1000 mg, about 80 mg to about 1000 mg, about 90 mg to about 1000 mg, about 100 mg to about 1000 mg, about 200 mg to 1000 mg, about 300 mg to about 1000 mg, about 400 mg to about 1000 mg, about 500 mg to about 1000 mg, about 1 mg to about 1000 mg. In some embodiments, the dosage unit may be administered to an individual 1 to 6 times daily, for example, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, etc. In some embodiments, the dosage unit may be administered to an individual 1 to 6 times daily, depending on the severity of the individual's symptoms.

[0343] In some embodiments, the pharmaceutical compositions of the present disclosure are formulated for oral administration in treatments of duration greater than 1 week, greater than 2 weeks, greater than 3 weeks, greater than 1 month, greater than 2 months, greater than 3 months, greater than 4 months, greater than 5 months, greater than 6 months, greater than 7 months, greater than 8 months, greater than 9 months, greater than 10 months, greater than 11 months, greater than 1 year, or even longer.

[0344] In some embodiments, pharmaceutical compositions of the present disclosure are formulated for parenteral administration, such as via intravenous, subcutaneous or intramuscular injection. In some embodiments, the unit dose for parenteral administration contains one or more compounds provided herein in an amount of about 0.1 mg to about 500 mg of one or more compounds provided herein, such as about 0.2 mg to about 500 mg, about 0.3 mg to about 500 mg, about 0.4 mg to about 500 mg, about 0.5 mg to about 500 mg, about 1 mg to about 500 mg, about 5 mg to about 500 mg, about 10 mg to about 500 mg, about 20 mg to about 500 mg, about 30 mg to about 500 mg, about 40 mg to about 500 mg, about 50 mg to about 500 mg, about 0.5 mg to about 400 mg, about 0.5 mg to about 300 mg, about 0.5 mg to about 200 mg, about 0.5 mg to about 100 mg, about 0.5 mg to about 90 mg, about 0.5 mg to about about 0.5 mg to about 100 mg, about 150 mg to about 200 mg, about 200 mg to about 700 mg, about 300 mg to about 600 mg, or about 400 mg to about 500 mg, such as about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, etc.

[0345] In some embodiments, pharmaceutical compositions intended for administration by injection may be prepared by combining one or more compounds of the present disclosure with sterile distilled water, sesame oil, peanut oil, or propylene glycol aqueous solution to form a solution. In some embodiments, the pharmaceutical composition may include a surfactant or other dissolving excipient, which is added to facilitate the formation of a homogeneous solution or suspension. In some embodiments, the pharmaceutical composition may further include one or more additional agents selected from the group consisting of a wetting agent, a suspending agent, a preservative, a buffer, and an isotonic agent.

[0346] In certain embodiments, the pharmaceutical composition intended to be administered by injection can be administered with a syringe. In certain embodiments, the syringe is disposable. In certain embodiments, the syringe is reusable. In certain embodiments, the syringe is pre-filled with a pharmaceutical composition provided herein.

[0347] In another aspect, a veterinary composition is also provided, comprising one or more molecules or compounds of the present disclosure or pharmaceutically acceptable salts thereof and a veterinary carrier. A veterinary carrier is a substance suitable for the purpose of administering the composition, and may be a solid, liquid or gaseous substance that is originally inert or acceptable in the veterinary field and is compatible with the active ingredient. These veterinary compositions can be administered parenterally, orally or by any other desired route.

[0348] Pharmaceutical compositions or veterinary compositions can be packaged in a variety of ways depending on the method for administering the drug. For example, the article for distribution may include a container in which a composition of suitable form is deposited. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, etc. The container may also include an anti-disassembly assembly to prevent easy access to the contents of the package. In addition, a label describing the contents of the container is attached to the container. The label may also include appropriate warnings. The composition may be packaged in a unit dose or multi-dose container (e.g., sealed ampoules and vials) and may be stored under a freeze-drying (lyophilized) condition, requiring only the addition of a sterile liquid carrier (e.g., water) for injection immediately before use. Ready-to-use injection solutions and suspensions are prepared by sterile powders, granules, and lozenges of the types described previously.

[0349] In another aspect, a pharmaceutical composition comprising one or more compounds of the present disclosure or a pharmaceutically acceptable salt thereof as a first active ingredient and a second active ingredient is also provided.

[0350] In some embodiments, the second active ingredient has complementary activities to the compounds provided herein such that they do not adversely affect each other. The ingredients are preferably present in combination in amounts effective for the intended purpose.

[0351] In some embodiments, the second active ingredient can be an antibiotic, a protease inhibitor, an antiviral agent, an anti-inflammatory agent, an immunomodulator, a kinase inhibitor, an antimetabolite, a lysosomal agent, an M2 proton channel blocker, a polymerase inhibitor (e.g., EIDD-2801), a neuraminidase inhibitor, a reverse transcriptase inhibitor, a viral entry inhibitor, an integrase inhibitor, an interferon (e.g., type I, type II, and type III), or a nucleoside analog.

[0352] In some embodiments, the second active ingredient is an antibiotic. In some embodiments, the antibiotic can be selected from penicillin antibiotics, quinolone antibiotics, tetracycline antibiotics, macrolide antibiotics, lincosamide antibiotics, cephalosporin antibiotics or RNA synthetase inhibitors. In some embodiments, the antibiotic is selected from azithromycin, vancomycin, metronidazole, gentamicin, colistin, fidaxomicin, telavancin, oritavancin, dalbavancin, daptomycin, cephalexin, cefuroxime, cefdroxil, cefazolin, cephalothin, cefaclor, cefmandole, cefoxitin, cefprozil, ceftobiprole, ciprofloxacin, levofloxacin, ofloxacin, gatifloxacin, moxifloxacin, norfloxacin, tetracycline, minocycline, Oxytetracycline, doxycycline, amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, methicillin, ertapenem, doripenem, imipenem / cilastatin, meropenem, amikacin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefoxotin, and streptomycin. In some embodiments, the antibiotic is azithromycin.

[0353] In some embodiments, the second active ingredient may be a protease inhibitor. In some embodiments, the protease inhibitor may be selected from nafamostat, camostat, gabexate, ε-aminocaproic acid, aprotinin, amprenavir, indinavir, nelfinavir, ritonavir and saquinavir.

[0354] In some embodiments, the second active ingredient can be an antiviral agent. In some embodiments, the antiviral agent can be selected from ribavirin, favipiravir, ST-193, oseltamivir, zanamivir, peramivir, danoprevir, ritonavir, remdesivir, cobicistat, elvitegravir, emtricitabine, tenofovir, tenofovir disoproxil, tenofovir alafenamide hemifumarate, abacavir, dolutegravir, efavirenz, elbasvir, ledipasvir, glecaprevir, sofosbuvir, bicagvir, dasabuvir, lamivudine, atazanavir, ombitasvir, lamivudine, stavudine, nevirapine, rilpivirine, paritaprevir, simeprevir , daclatasvir, grazoprevir, pibrentasvir, adefovir, amprenavir, ampligen, alaviroc, anti-goat antibody, balavir, cabotegravir, cytarabine, ecoliever, epigallocatechin gallate, etravirine, fostemsavir, gemcitabine, griffithsin, imunovir, indinavir, maraviroc, methylthiazone, MK-2048, nelfinavir, nevirapine, nitazoxanide, ritonavir (norvir), plerixafor, PRO 140, raltegravir, pyramididine, saquinavir, telbivudine, TNX-355, valacyclovir, VIR-576, and zalcitabine.

[0355] In some embodiments, the second active ingredient can be an anti-inflammatory agent. In some embodiments, the anti-inflammatory agent can be selected from antihistamines, corticosteroids (e.g., fluticasone propionate, fluticasone furoate, beclomethasone dipropionate, budesonide, ciclesonide, mometasone furoate, triamcinolone, flunisolide), NSAIDs, leukotriene modifiers (e.g., montelukast, zafirlukast, pranlukast), tryptase inhibitors, IKK2 inhibitors, p38 inhibitors, Syk inhibitors, protease inhibitors such as elastase inhibitors, integrin antagonists (e.g., beta-2 integrin antagonists), adenosine A2a agonists, mediator release inhibitors such as sodium cromoglycate, 5-lipoxygenase inhibitors (zyflo), DPI antagonists, DP2 antagonists, PI3Kδ inhibitors, GGK inhibitors, LP (lysophospholipid) inhibitors Preparations or FLAP (5-lipoxygenase activating protein) inhibitors, bronchodilators (e.g., muscarinic antagonists, beta-2 agonists), methotrexate and similar agents; monoclonal antibody therapy, such as anti-IgE, anti-TNF, anti-IL-5, anti-IL-6, anti-IL-12, anti-IL-1 and similar agents; cytokine receptor therapy, such as etanercept and similar agents; antigen non-specific immunotherapy (e.g., interferon or other cytokines / chemokines, chemokine receptor modulators such as CCR3, CCR4 or CXCR2 antagonists, other cytokine / chemokine agonists or antagonists, TLR agonists and similar agents), suitable anti-infective agents (including antibiotics, antifungals, anthelmintics, antimalarials, antiprotozoals and anti-tuberculosis agents).

[0356] In some embodiments, the second active ingredient can be an immunomodulator. In some embodiments, the immunomodulator can be selected from anti-PD-1 or anti-PDL-1 therapeutic agents, including pembrolizumab, nivolumab, atezolizumab, durvalumab, BMS-936559 or avelumab, anti-TIM3 (anti-HAVcr2) therapeutic agents (including but not limited to TSR-022 or MBG453), anti-LAG3 therapeutic agents (including but not limited to relalizumab, LAG525 or TSR-033), anti-4-1BB (anti-CD37, anti-TNFRSF9), CD40 agonist therapeutic agents (including but not limited to SGN-40, CP-870,893 or R0 7009789), anti-CD47 therapeutics (including but not limited to Hu5F9-G4), anti-CD20 therapeutics, anti-CD38 therapeutics, STING agonists (including but not limited to ADU-S100, MK-1454, ASA404 or amide benzimidazole), anthracyclines (including but not limited to doxorubicin or mitoxantrone), demethylating agents (including but not limited to azacytidine or decitabine), other immunomodulatory therapeutics (including but not limited to epidermal growth factor inhibitors, statins, metformin, angiotensin receptor blockers, thalidomide, lenalidomide, pomalidomide, prednisone or dexamethasone). In some embodiments, the additional therapeutic agent is a p2-adrenergic receptor agonist, including but not limited to vilanterol, salmeterol, salbutamol, formoterol, salmethamine, fenoterol, carmoterol, etanterol, naminaterol, clenbuterol, pirbuterol, flubuterol, reproterol, bambuterol, indacaterol, terbutaline and salts thereof, such as the xinafoate (1-hydroxy-2-naphthoic acid) salt of salmeterol, the sulfate salt of salbutamol, or the fumarate salt of formoterol.

[0357] In some embodiments, the second active ingredient can be a kinase inhibitor. In some embodiments, the kinase inhibitor can be selected from erlotinib, gefitinib, neratinib, afatinib, osimertinib, lapatinib, crizotinib, brigatinib, ceritinib, alectinib, lorlatinib, everolimus, sirolimus, abemaciclib, LEE011, palbociclib, cabozantinib, sunitinib, pazopanib, sorafenib, regorafenib, sunitinib, axitinib, dasatinib, imatinib, nilotinib, ponatinib, idelalisib, ibrutinib, Loxo 292, larotrectinib and quizartinib.

[0358] Methods of treating diseases

[0359] In another aspect, the present disclosure provides a method for treating a viral infection in a patient in need thereof, the method comprising administering an effective amount of any of the compounds described herein.

[0360] In some embodiments, the virus infection is from the following viruses: RNA virus, DNA virus, coronavirus, papillomavirus, pneumovirus, small RNA virus, influenza virus, adenovirus, cytomegalovirus, polyomavirus, poxvirus, rhinovirus, norovirus, flavivirus, alphavirus, Ebola virus, measles virus, enterovirus, orthopneumovirus, slow virus, arenavirus, herpes virus and hepatovirus. In certain embodiments, the virus infection is a coronavirus infection. In some embodiments, the virus infection is selected from the following coronaviruses: 229Eα coronavirus, NL63α coronavirus, OC43β coronavirus, HKU1β coronavirus, Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) and SARS-CoV-2 (COVID-19). In certain embodiments, the virus infection is SARS-CoV-2.

[0361] In some embodiments, the viral infection is from a virus selected from the group consisting of: Calicivirus, MD145, Murine Norovirus, Swine Herpes Virus, Rabbit Hemorrhagic Disease Virus, Porcine Teschovirus, Bovine Coronavirus, Feline Infectious Peritonitis Virus, EV-68 Virus, EV-71 Virus, Poliovirus, Norovirus, Human Rhinovirus (HRV), Hepatitis A Virus (HAV), and Foot-and-Mouth Disease Virus (FMDV).

[0362] In some embodiments, the viral infection is an arenavirus infection. In certain embodiments, the arenavirus is selected from the group consisting of Junin virus, Lassa virus, Louyo virus, Machupo virus, and Sabia virus. In some embodiments, the viral infection is an influenza infection. In certain embodiments, the influenza is influenza H1N1, H3N2, or H5N1.

[0363] In some embodiments, the methods described herein can inhibit viral replication, propagation, replication, assembly or release, or minimize the expression of viral proteins. In one embodiment, described herein are methods of inhibiting viral propagation, methods of inhibiting viral replication, methods of minimizing the expression of viral proteins, or methods of inhibiting viral release, comprising administering a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof to a patient infected with the virus, and / or contacting an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof with a virus-infected cell.

[0364] In some embodiments, the methods described herein do not include administering to the subject an oxidase inhibitor. In certain embodiments, the methods described herein do not include administering ritonavir or cobicistat in combination with any compound described herein.

[0365] In yet another aspect, the present disclosure provides a method for inhibiting 3-chymotrypsin-like protease in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound provided herein or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0366] Example

[0367] The following examples are included for illustrative purposes. However, it should be understood that these examples do not limit the present disclosure and are intended only to propose methods for implementing the present disclosure. Those skilled in the art will recognize that the chemical reactions described can be easily adapted to prepare many other compounds of the present disclosure, and alternative methods for preparing compounds of the present disclosure are considered to be within the scope of the present disclosure. For example, the synthesis of non-illustrative compounds according to the present disclosure can be successfully carried out by modifications that are obvious to those skilled in the art, such as by appropriately protecting interfering groups, by utilizing other suitable reagents and building blocks known in the art in addition to those described, and / or by making conventional modifications to reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be considered to be applicable to the preparation of other compounds of the present disclosure.

[0368] Example 1

[0369] Example 1.1 Synthesis of intermediates s1 and s2

[0370]

[0371] Step 1: Synthesis of s1-2

[0372] A mixture of (S)-1-tert-butyl 4-methyl 2-aminosuccinate hydrochloride (100.0 g, 0.42 mol), 9-bromo-9-phenylfluorene (161.8 g, 0.5 mol, 1.2 equivalents) and K3PO4 (178.1 g, 0.84 mol, 2 equivalents) in CH3NO2 (1000 mL) was stirred at 35 ° C for 16 hours. After cooling to ambient temperature, the reaction mixture was filtered to remove salt. The filtrate was diluted with CH3OH (20 mL), and the resulting solution was stirred at ambient temperature for 1 hour. The mixture was concentrated by evaporation, and the residue was purified by silica gel column chromatography, eluted with hexane and EtOAc in a 10: 1 volume ratio to obtain compound s1-2 (157 g, 85%) as a viscous oil.

[0373] MS (ESI+) [(M+H) + ]444.20

[0374] 1H NMR (400MHz, CDCl3) δ7.69-7.65(m,2H),7.41–7.19(m,11H),3.65(s,3H),3.35(br s,1H),2.86(dd,J=5.6,12.8Hz,1H),2.45(dd,J=5.6,14.8Hz,1H),2.30(dd,J=5.6,14.8Hz,1H),1.24(s,9H).

[0375] Step 2: Synthesis of s1-3

[0376] At -78 ° C and N2, a KHMDS solution (525 mL, 1M THF solution) was added to a solution of compound s1-2 (157 g, 0.35 mol) in anhydrous THF (1000 mL) over 30 minutes. After 30 minutes, the reactant was warmed to -40 ° C, and then MeI (0.25 mL, 0.525 mol) was slowly added. The mixture was then stirred at 0 ° C for 1.5 hours. The reaction mixture was then cooled to -78 ° C again, and another batch of KHMDS (525 mL, 1M THF solution) and MeI (0.25 mL, 0.525 mol) were added in the same manner as above. After adding MeI, the reaction mixture was stirred at 0 ° C for 16 hours. The reactant was quenched with saturated NH4Cl (500 mL) and H2O (500 mL). The mixture was extracted three times with EtOAc. The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography eluting with 3% hexanes in EtOAc / hexanes to give compound s1-3 (121 g, 72%) as a colorless oil.

[0377] MS (ESI+) [(M+H) + ]472.30

[0378] 1 H NMR (400MHz, CDCl3) δ7.68-7.65(m,2H),7.41-7.20(m,11H),3.53(s,3H),2.85-2.77(m,1H),1.17(s,3H),1.11(s,9H),1.05(s,3H).

[0379] Step 3: Synthesis of s1-4

[0380] Under nitrogen atmosphere, a solution of compound s1-3 (121 g, 0.26 mol) in anhydrous DCM (1000 mL) was cooled to -78 ° C. Then a hexane solution of DIBAL-H (770 mL, 1 M THF solution) was added to the above solution over 40 minutes. After stirring at -78 ° C for 30 minutes, saturated Rochelle salt (500 mL) was added to quench the reactant, followed by Et2O (200 mL). The mixture was warmed to ambient temperature and stirred for 15 minutes. The water layer was extracted twice with Et2O. The combined organic extracts were washed with brine, dried over anhydrous MgSO4 and concentrated to give a crude compound s1-4 (86 g) in an oily state, which was used directly in the next step without further purification.

[0381] MS (ESI+) [(M+H) + ]444.2

[0382] 1 H NMR (400MHz, CDCl3) δ7.69-7.66(m,2H),7.46(d,J=8.0Hz,1H),7.36-7.11(m,10H),3.27(s,2H),1.12(s,9H),0.98(s,3H),0.65(s,3H).

[0383] Step 4: Synthesis of s1-5

[0384] To compound s1-4 (86g, 0.19mol) in the mixed solvent of methanol (450mL) and acetic acid (30mL) add wet 10% Pd / C (9g), and add H2 three times in the obtained suspension, and stir overnight at ambient temperature under H2 (1atm). The reaction mixture is filtered through diatomite, and the catalyst is washed with MeOH. The filtrate merged is concentrated. Residue is distributed between 300mL H2O and 300mL Et2O. The organic layer is washed with 100mL of 0.5M H3PO4, and the aqueous layer is adjusted to pH 9 with saturated Na2CO3, then extracted with DCM (3′200mL). The organic layer is dried and evaporated to obtain the crude compound s1-5 (29.6g) of about 85% yield, which can be used for the next step without further purification.

[0385] MS (ESI+) [(M+H) + ]204.10

[0386] 1H NMR (400MHz, CDCl3) δ3.60-3.57(m,1H),3.32–3.28(m,2H),2.64(br s,2H),1.45(s,9H),0.98(s,3H),0.87(s,3H).

[0387] Step 5: Synthesis of s1

[0388] To a stirred solution of compound s1-5 (29.6 g, 0.15 mol) and pyridine (17.3 g, 0.22 mmol) in 500 mL of MeCN was added a solution of benzyloxyphosgene (29.8 g, 0.17 mmol) in 80 mL of MeCN at 0 ° C, and the mixture was stirred at 0 ° C for 90 minutes. The reactant was quenched with water and extracted with EtOAc. The combined organic layer was dried and evaporated, and the residue was purified by silica gel chromatography, eluted with 10% EtOAc in hexane to give compound s1 (29.1 g).

[0389] MS (ESI+) [M+Na] + =360.20

[0390] 1 H NMR(400MHz, CDCl3)δ:7.41-7.33(m,5H),5.68(d,J=8.5Hz,1H),5.20-5.08(m,2H),4.27(d,J=8.5Hz,1H),3.59(dd,J =5.3,9.5Hz,1H),3.45(dd,J=5.3,12.0Hz,1H),3.11(dd,J=9.8,11.8Hz,1H),1.51(s,9H),1.13(s,3H),0.78(s,3H).

[0391] Step 6: Synthesis of s2

[0392] To a solution of compound s1 (10.0 g, 29.6 mmol) in DCM (100 mL) was added DMP (25.1 g, 59.2 mmol) at 0°C, and the mixture was stirred at 0°C-20°C for 2 hours. The reaction was quenched with saturated NaHCO (50 mL) and Na2S2O3 (50 mL), and then stirred at 20°C for another 0.5 hours. The two phases were separated, and the organic layer was dried over Na2SO4, filtered and concentrated. The residue was then purified by silica gel chromatography (PE:EA=2:1) ​​to give compound s2 (8.4 g, 85%) as a white solid.

[0393] 1HNMR (400MHz, CDCl3) δ9.58 (s, 1H), 7.38–7.29 (m, 5H), 5.42 (d, J = 8Hz, 1H), 5 .14-5.12(m,2H),4.42(d,J=8Hz,1H),1.42(s,9H),1.09(s,3H),0.99(s,3H).

[0394] LC-MS[M+Na] + =358.2

[0395] Example 1.2 Synthesis of intermediate s3

[0396]

[0397] Step 1: Synthesis of s3-1

[0398] To a solution of methyl(triphenyl)phosphonium bromide (6.8 g, 19.1 mmol) in THF (50 mL) was added NaHMDS (1 M, 19.1 mL) at 0°C. The mixture was stirred at 0°C for 1 hour. A solution of compound s2 (3.2 g, 9.5 mmol) in THF (20 mL) was then added dropwise to the above reaction mixture. The mixture was stirred at 25°C for 3 hours. TLC showed that compound s2 was completely consumed and a major new spot with lower polarity was detected. The reactants were quenched with saturated NH4Cl (100 mL). The two phases were separated, and the aqueous phase was extracted with EA (100 mL*3) at 0°C. The combined organic layers were washed with 100 mL of brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography ( 40g Purification by silica gel flash column, eluting with a gradient of 0% to 40% ethyl acetate / petroleum ether, at 40 mL / min) afforded compound s3-1 (2.5 g, 78%) as a colorless oil.

[0399] 1 H NMR (400 MHz, chloroform-d) δ = 7.34-7.20 (m, 5H), 5.78 (dd, J = 10.8, 17.2 Hz, 1H), 5.22-5.02 (m, 3H), 5.01-4.90 (m, 2H), 4.03 (d, J = 9.2 Hz, 1H), 1.36 (s, 9H), 1.05-0.99 (m, 6H).

[0400] Step 2: Synthesis of s3

[0401] 9-BBN (0.5 M, 10.8 mL) was slowly added to a solution of compound s3-1 (600 mg, 1.8 mmol) in THF (20 mL) at 0°C over 10 minutes. The resulting clear solution was stirred at 25°C for 10 hours. The mixture solution was cooled to 0°C, and then saturated Na2CO3 (5 mL) was added, followed by H2O2 (1.59 mL, 16.6 mmol, 30% purity). The mixture was stirred at 0°C for 2 hours. LC-MS showed that compound s3-1 was completely consumed and a major peak with the desired mass was detected. The mixture was quenched by the addition of sodium sulfite (100 mL of a 10 wt % solution) and extracted with ethyl acetate (100 mL). The organic layer was washed with brine (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography ( 40g Purification by silica gel flash column, eluting with 0% to 30% THF / petroleum ether gradient, at 40 mL / min) afforded compound s3 (430 mg, 68%) as a colorless oil.

[0402] LCMS: [M+H] + =352.4

[0403] 1 H NMR (500MHz, CDCl3) δ = 7.29-7.18 (m, 5H), 5.67 (br d, J = 9.6Hz, 1H), 5.05-4.96 (m, 2H), 4.18 (br d,J=9.8Hz,1H),3.72-3.60(m,2H),2.17-1.88(m,1H),1.62-1.51(m,1H),1.37(s,9H),0.94-0.84(m,6H).

[0404] Example 1.3 Synthesis of intermediate s4

[0405]

[0406] Step 1: Synthesis of s4-1

[0407] To a stirred solution of compound s1 (29.1 g, 0.086 mol) and triethylamine (26 g, 0.25 mmol) in DCM (300 mL) was added a solution of MsCl (14.7 g, 0.13 mmol) in DCM (80 mL) at 0 ° C. The mixture was stirred at 25 ° C for 3 hours. The reactant was then quenched with H2O. The two phases were separated, and the aqueous layer was extracted with DCM (100 mL'3). The combined organic layers were dried and evaporated, and the residue was purified by chromatography to give compound s4-1 (33.9 g, 95%) as a white solid.

[0408] 1 H NMR (400MHz, CDCl3) δ7.35-7.24(m,5H),5.45-5.35(m,1H),5.13-5.07(m,2H),4.27(d,J =8.0Hz,1H),3.96(q,J=8.0Hz,2H),2.97(s,3H),1.46(s,9H),1.05(s,3H),1.00(s,3H).

[0409] Step 2: Synthesis of s4-2

[0410] To a stirred solution of compound s4-1 (33.9 g, 0.082 mol) in anhydrous HMPA (250 mL) was added NaN3 (53 g, 0.82 mol) at 0°C. The mixture was stirred at 95°C for 24 hours. The reactants were cooled to ambient temperature. The mixture was filtered and the filtrate was extracted three times with EtOAc. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to give a residue, which was purified by silica gel chromatography using EtOAc / hexane (7%) as eluent to give compound s4-2 (14.0 g) as a colorless oil.

[0411] MS (ESI+) [(M+H) + ]363.2

[0412] 1 H NMR (400MHz, CDCl3) δ7.38-7.30(m,5H),5.45(d,J=9.2Hz,1H),5.15-5.08(m,2H),4.23(d,J=9. 2Hz,1H),3.29(d,J=12.0Hz,1H),3.23(d,J=12.0Hz,1H),1.48(s.9H),1.00(s,3H),0.98(s,3H).

[0413] Step 3: Synthesis of s4

[0414] Triphenylphosphine (14.2 g, 0.054 mol) was added to a solution of compound s4-2 (14 g, 0.039 mol) in anhydrous THF (150 mL), and the reaction was warmed to 65 ° C and stirred for 22 hours. H2O (13 mL) was then added, and the reaction was stirred for another 2 hours. The reaction was concentrated under reduced pressure, and the residue was purified by chromatography to obtain compound s4 (8.3 g) as a colorless oil.

[0415] MS (ESI+) [(M+H) + ]337.2

[0416] 1 H NMR (400MHz, CDCl3) δ7.35-7.31(m,5H),6.29(d,J=8.0Hz,1H).5.11-5.08(m,2H),4.15(d,J= 8.0Hz,1H),2.67(d,J=16Hz,1H),2.46(d,J=16Hz,1H),1.46(s,9H),0.98(s,3H),0.88(s,3H).

[0417] Example 1.4 Synthesis of intermediate s5

[0418]

[0419] To a solution of compound s2 (8.4 g, 25.0 mmol) in methanol (85 mL) was added CH3NH2.HCl (2.5 g, 37.5 mmol), CH3COOH (1.5 g, 25.0 mmol) and NaBH3CN (3.1 g, 50.0 mmol), and the mixture was stirred at 20 ° C for 16 hours. The suspension was quenched with saturated NaHCO3 (50 mL) and then extracted with DCM (50 mL * 2). The combined organic layers were concentrated and purified by silica gel chromatography (PE: EA = 1: 2) to give compound s5 (2.93 g, 33%) as a light yellow oil.

[0420] LC-MS [M+H] + =351.2

[0421] 1 H NMR (400MHz, CDCl3) δ7.38-7.30(m,5H),7.07(d,J=6.4Hz,1H),5.14-5.06(m, 2H),4.04(d,J=6.8Hz,1H),2.60(d,J=12.4Hz,1H),2.40-2.37(m,4H),1.96(br s,1H),1.47(s,9H),1.08(s,3H),0.95(s,3H).

[0422] Example 1.5 Synthesis of intermediate s6

[0423]

[0424] Step 1: Synthesis of s6-2

[0425] LiHMDS (184 mL, 184 mmol, 1N THF solution) was added dropwise to a solution of compound s6-1 (30 g, 123 mmol) in THF (1000 mL) at -78 ° C. After stirring at -78 ° C for 1 hour, allyl iodide (21 g, 123 mmol) was added dropwise, and the resulting mixture was further stirred at -78 ° C for 1 hour. The reactant was quenched with saturated NH4Cl (300 mL). The two phases were separated, and the aqueous phase was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a crude product, which was purified by flash silica gel chromatography, eluted with 10% EtOAc / petroleum ether to give compound s6-2 (13.5 g, 38.6%) as a colorless oil and s6a-1 (5.8 g, 16.6%) as a colorless oil.

[0426] s6-2:

[0427] MS (ESI+) [(2M+H) + ]589.3.

[0428] 1 H NMR (400 MHz, methanol-d4) δ 5.82–5.71 (m, 1H), 5.14–5.04 (m, 2H), 4.65-4.62 (m, 1H), 3.78 (s, 3H), 2.77-2.69 (m, 1H), 2.59–2.50 (m, 1H), 2.25–2.03 (m, 3H), 1.47 (s, 9H).

[0429] s6a-1:

[0430] MS (ESI+) [(2M+H) + ]589.3.

[0431] 1 H NMR (400MHz, CDCl3) δ5.68-5.61(m,1H),4.99-4.95(m,2H),4.42(d,J=8.0Hz,1H),3.68(s,3 H),2.58-2.52(m,2H),2.40-2.37(m,1H),2.14-2.12(m,1H),1.64-1.59(m,1H),1.39(s,9H).

[0432] Step 2: Synthesis of s6-3

[0433] A mixture of compound s6-2 (60.0 g, 0.2 mol) in DCM (600 mL) was bubbled with O3 at -78 ° C for 4 hours. Me2S (131.3 g, 2.1 mol) was then added dropwise. The mixture was stirred at 25 ° C for 16 hours. The reaction mixture was then concentrated to give a yellow oil. The residue was dissolved in EtOAc (1 L) and washed with brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography, eluted with petroleum ether and ethyl acetate (1: 1 volume ratio) to give compound s6-3 (7.00 mg, 58.5%) as a white solid.

[0434] MS observed value (ESI+) [(M+H) + ]285.

[0435] Step 3: Synthesis of s6-5

[0436] A mixture of compound s6-3 (23 g, 80.62 mmol) and (2R)-2-amino-2-phenylethanol (13.27 g, 96.74 mmol) in CHCl (900 mL) was stirred at 0 ° C for 1 hour. Then TMSCN (20.81 g, 210.16 mmol) was added and the resulting mixture was stirred at 0 ° C for 1 hour. Finally, triethylamine trihydrofluoride (20.33 g, 126.10 mmol) was added at 0 ° C and the mixture was stirred at 0 ° C for 1 hour. The mixture was concentrated and then dissolved with EtOAc (500 mL), and the organic layer was washed with brine and dried over anhydrous Na2SO4. After concentration, the residue was crystallized with petroleum ether and EtOAc (1: 10 volume) to obtain compound s6-5 (12.00 g, crude product) as a white solid.

[0437] LCMS: m / z = 432.2 [M+1] + ;

[0438] 1 H NMR (400MHz, CDCl3) δ7.384-7.26(m,5H),5.07(t,J=5.6Hz,1H),4.5(d,J=8.8,1H),3.84-3.82(m,1H),3.78(s,3H),3.43-3.38(m,2H) ,3.24-3.18(m.1H),3.09(d,J=12.0Hz,1H),2.89-2.80(m,1H),2.24-2.18(m,1H),1.96-1.89(m,1H),1.78-1.62(m,2H),1.39(s,9H).

[0439] Step 4: Synthesis of s6-6

[0440] Pb(AcO)4(18.48g, 41.72mmol) was added to a mixture of compound s6-5(10g, 23.18mmol) in DCM(50mL) and methanol(50mL) at 0°C. After addition, the mixture was stirred at 0°C for 10 minutes, then a buffer solution (Na2HPO4 / NaH2PO4 aqueous solution, 300mL) was added, and the reactant was stirred at 25°C for 1 hour. The mixture was filtered, and the filtrate was extracted with DCM(50mL′2). The combined organic layers were concentrated, and the residue was dissolved with MTBE(200mL). 3N HCl(200mL) was added to the above mixture, and the mixture was distributed. The aqueous layer was collected and adjusted to pH=8 with solid NaHCO3. The resulting mixture was extracted with ethyl acetate (50 mL'2), the organic layer was washed with brine, dried over Na2SO4, and concentrated to give crude compound s6-6 (5.00 g, crude) as a colorless oil, which was used in the next step without further purification.

[0441] MS (ESI+) [(M+H) + ]312.1.

[0442] Step 5: Synthesis of s6-8

[0443] HATU (1.47 g, 3.85 mmol) was added to a DMF (10 mL) solution of compound s6-7 (820.0 mg, 3.21 mmol). After the addition, the mixture was stirred at 25 ° C for 30 minutes, and then compound s6-6 (1.0 g, 3.21 mmol) and DIEA (830.25 mg, 6.42 mmol) were added. The resulting mixture was stirred at 25 ° C for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL'2). The organic layer was washed with water (20 mL) and brine, dried over Na2SO4, concentrated and purified by flash silica gel chromatography, eluted with 16% to 33% EtOAc / petroleum ether to obtain compound s6-8 (1.10 g, 53.2% yield) as a white solid.

[0444] MS (ESI+) [(M+Na) + ]571.3

[0445] 1H NMR (400MHz, CDCl3) δ5.01-4.94(m,1H),4.63–4.54(m,1H),4.10-4.04(m,1H),3.76(s,3H),3.52-3.42(m,2H),2. 69-2.61(m,1H),2.41-2.31(m,2H),2.03-1.67(m,4H),1.48(s,9H),1.42(s,9H),1.03(s,3H),0.89-0.87(m,3H).

[0446] Step 6: Synthesis of s6

[0447] Trimethyltin hydroxide (2.39 g, 4.01 mmol) was added to a toluene (2 mL) solution of compound s6-8 (1.1 g, 2.01 mmol), and after addition, the mixture was stirred at 100 ° C for 12 hours. When the reaction was complete, the reactant was concentrated, and the residue was dissolved in EtOAc (20 mL). Triethylamine trihydrofluoride (3.2 g, 8.02 mmol) was then added, and the mixture was stirred at 25 ° C for 2 hours. Water (20 mL) was added, and the resulting slurry was filtered. The filtrate was concentrated to obtain compound s6 (1.21 g, crude product) as a white solid. The compound can be used in the next step without further purification.

[0448] MS (ESI+) [(M+Na) + ]557.3

[0449] Example 1.6 Synthesis of intermediate s6a

[0450] Intermediate S6a was prepared from S6a-1 following similar chemistry and procedures as described above.

[0451]

[0452] LCMS: m / z = 535.30 [M+1] +

[0453] Example 1.7 Synthesis of intermediates s7-s11 and compound 76

[0454]

[0455] Step 1: Synthesis of s7-1

[0456] At 25 ° C, DCC (2.32 g, 11.22 mmol) and DMAP (0.228 g, 1.87 mmol) were added to a DCM (30 mL) solution of compound s1 (2.52 g, 7.48 mmol) and compound s6 (4.0 g, 7.48 mmol), and the mixture was stirred at 25 ° C for 16 hours. The reaction mixture was then washed twice with water (30 mL * 2). The organic layer was dried over Na2SO4, filtered and concentrated to give a residue, which was purified by silica gel chromatography (PE: EA = 1: 1) to give s7-1 (2.1 g, 33%) as a white solid.

[0457] LC-MS[M-199] + =654.4

[0458] 1 HNMR(400MHz, CDCl3)δ7.32-7.23(m,5H),5.41-5.33(m,1H),5.12-4.82(m,3H),4. 62-4.53(m,1H),4.04-3.93(m,2H),3.87-3.81(m,1H),3.72-3.63(m,1H),3.46-3. 33(m,1H),2.88-2.73(m,1H),2.62-2.39(m,1H),2.31-2.23(m,1H),2.01-1.84(m, 2H),1.61-1.51(m,2H),1.43-1.34(m,27H),9.94-0.91(m,9H),0.87-0.79(m,3H).

[0459] Step 2: Synthesis of s7-2

[0460] To a solution of s7-1 (2.1 g, 2.46 mmol) in TFA (10 mL) and ACN (10 mL) was added anisole (0.40 g, 3.69 mmol). The mixture was stirred at 25 ° C for 16 hours. The suspension was concentrated, and the residue was purified by reverse phase column (ACN: H2O = 55:45) to give compound s7-2 (730 mg, 50%) as a white solid, which was used directly in the next step.

[0461] LC-MS [M+H] + =598.3

[0462] Step 3: Synthesis of compound 76

[0463] To a solution of s7-2 (630 mg, 1.05 mmol) in DMF (12 mL) was added HATU (1.0 g, 2.64 mmol) and DIEA (681.17 mg, 5.27 mmol). The reaction mixture was stirred at 30 °C for 2 hours. The suspension was concentrated and the residue was purified by reverse phase column to give compound 76 (300 mg, 49%).

[0464] LC-MS [M+H] + =580.3

[0465] 1 HNMR(400MHz, methanol-D4)δ7.38-7.26(m,5H),5.13-5.01(m,3H),4.90-4.86(m,2H) ,4.33(s,1H),4.08-4.06(m,2H),4.02-3.97(m,1H),3.88-3.85(m,1H),2.96-2. 92(m,1H),2.47-2.33(m,2H),1.98-1.90(m,1H),1.81-1.74(m,1H),1.65-1.58 (m,1H),1.38-1.33(m,1H),1.21(s,3H),1.06(s,3H),0.98(s,3H),0.85(s,3H).

[0466] Step 4: Synthesis of s7

[0467] To a solution of compound 76 (60 mg, 103 μmol) in THF (4 mL) was added Pd / C (120 mg) under H2, and H2 was added to the reaction mixture three times, and stirred at 25° C. for 2 hours. The reaction solution was filtered, and the filtrate was concentrated to give s7 (23.0 mg, 48%) as a colorless oil, which was used directly in the next step.

[0468] LC-MS [M+H] + =446.2

[0469] Intermediates s8, s9 and s10 were prepared following similar chemistry and procedures as described above.

[0470] Intermediate s8 was prepared from s3 and s6.

[0471]

[0472] LC-MS[M+1] + =460.20

[0473] Intermediate S9 was prepared from S4 and S6.

[0474]

[0475] LCMS: [M+1] + m / z=541.20;[M-1] + m / z = 539.20;

[0476] Intermediate s10 was prepared from s5 and s6.

[0477]

[0478] LC-MS [M+H] + =459.4

[0479] Intermediate S11 was prepared from S4 and S6a.

[0480]

[0481] LC-MS[M+1] + =445.20

[0482] Compound 146 was prepared following similar chemical reactions and procedures as described above.

[0483] LCMS: m / z = 579.30 [M+1] +,

[0484] 1 H NMR (400 MHz, methanol-d4) δ7.60-7.55 (m, 1H), 7.30-7.25 (m, 5H), 5.14-5.07 (m, 2H), 5.01 (d, J=12.9 Hz, 1H), 4.34 (s, 1H), 4.12 (s, 1H), 3.97-3.88 (m, 3H), 3.36-3.30 (m, 1H), 3 .07-3.03(m,2H),2.40–2.29(m,2H),2.22–2.11(m,1H),1.80-1.75(m,1H),1.65-1.6 0(m,1H),1.40(d,J=7.4Hz,1H),1.05(s,3H),1.01(s,3H),0.98(s,3H),0.85(s,3H).

[0485] Example 1.8 Synthesis of Compound 1

[0486] To a solution of s9 (11.6 mg, 0.026 mmol) in MeOH (1 mL) at 0°C and N2, TEA (78 mg, 0.78 mmol, 30 equiv) and methyl 2,2,2-trifluoroacetate (99.7 mg, 0.78 mmol, 30 equiv) were added. The mixture was stirred at 80°C for 16 hours. The reaction was cooled and concentrated to give a crude product, which was purified by preparative HPLC (MeCN / H2O, additive: 0.1% FA) to give compound 1 (4.1 mg).

[0487] LCMS: m / z=541.20[M+1] + ; m / z = 539.20 [M-1] + ;

[0488] 1 H NMR(400MHz, CD3OD)δ:5.38-5.30(m,1H),4.90-4.86(m,1H),4.59(s,1H),4.05-3.95(m,2H),3.86(d,J=8.0Hz,1H),3.41-3.37(m,1 H),3.13-3.10(m,2H),2.40-2.30(m,2H),2.20-2.17(m,2H),1.29-1.25(m,2H),1.08(s,3H),1.07(s,3H),0.98(s,3H),0.91(s,3H).

[0489] Compound 77 was prepared following similar chemical reactions and procedures as described above.

[0490] LC-MS [M+1]+=541.25

[0491] 1 H NMR(400MHz,CD3OD)δ:9.12(d,J=8.0Hz,1H),7.63-7.60(m,1H),5.12-5.08(m,1H),4.72 (s,1H),4.14(s,1H),4.05-3.95(m,2H),3.83(d,J=8.0Hz,1H),3.41-3.37(m,1H),3.13-3 .10(m,2H),2.38-2.33(m,2H),2.20-2.17(m,1H),1.83-1.80(m,1H),1.68-1.62(m,1H),1 .44-1.42(m,1H),1.29-1.25(m,1H),1.08(s,3H),1.07(s,3H),0.97(s,3H),0.89(s,3H).

[0492] Example 1.9 Synthesis of Compound 140

[0493] To a solution of s9 (12.0 mg, 0.027 mmol, 1 eq) in MeOH (1 mL) at 0°C and N2, HOBt (3.65 mg, 0.027 mmol, 1 eq), EDCI (5.2 mg, 0.027 mmol, 1 eq) and DIEA (8.7 mg, 0.068 mmol, 3 eq) were added. After stirring for 5 minutes, cyclopropanecarboxylic acid (2.3 mg, 0.027 mmol, 1 eq) was slowly added at -5°C, and the mixture was stirred at -5°C to RT for 1 hour. After the reaction was completed, the reactant was concentrated under reduced pressure, and the residue was purified by preparative HPLC (MeCN / H2O, additive: 0.1% FA) to give compound 140 (3.7 mg).

[0494] LCMS: m / z = 513.45 [M+1] + ; m / z = 511.45 [M-1] + ;

[0495] The following compounds were prepared following similar chemical reactions and procedures as described above.

[0496] Compound 122 was prepared from intermediate s7.

[0497] LCMS: m / z=542.4[M+1]+, m / z=540.2[M-1]-;

[0498] 1 H NMR(400MHz, methanol-d4)δ5.16–5.07(m,1H),4.95-4.90(m,1H),4.68(s,1H),4.17–3 .98(m,3H),3.84-3.81(m,1H),3.43-3.40(m,1H),2.98-2.94(m,1H),2.48-2.36 (m,2H),2.03–1.93(m,1H),1.84–1.75(m,1H),1.71–1.64(m,1H),1.41(d,J=7.6 Hz,1H),1.32-1.28(m,1H),1.26(s,3H),1.07(s,3H),0.98(s,3H),0.90(s,3H).

[0499] Compound 132 was prepared from intermediate s9.

[0500] 1H NMR (400MHz, CD3OD) δ9.13(d,J=8.0Hz,1H),8.42(d,J=9.6Hz,1H),7.57(d,J=6.4Hz,1H),7.03-7.00(m,2 H),6.84(t,J=8.8Hz,1H),5.15–5.06(m,1H),4.69(d,J=8.0Hz,1H),4.62(s,1H),4.13(s,1H),4.03–3.98( m,2H),3.92-3.88(m,1H),3.42-3.37(m,1H),3.10-3.05(m,2H),2.36-2.30(m,2H),2.23-2.18(m,1H),1.8 1-1.75(m,1H),1.66–1.61(m,1H),1.42-1.29(m,2H),1.07(s,3H),1.06(s,3H),0.96(s,3H),0.84(s,3H).

[0501] Compound 137 was prepared from intermediate s9.

[0502] LCMS: m / z = 607.50 [M+1] + ,m / z=605.45[M-1] - ;

[0503] 1 H NMR(400MHz,CD3OD)δ:6.99-6.95(m,2H),6.93-6.87(m,1H),5.12-5.06(m,1H),4.80-4.77(m,1H ),4.37-4.26(m,2H),4.17(s,1H),4.09-4.02(m,1H),3.99-3.89(m,2H),3.41-3.36(m,1H),3.14 -3.01(m,1H),2.39-2.30(m,2H),2.21(s,6H),2.18-2.13(m,1H),1.84-1.74(m,1H),1.68-1.64( m,1H),1.44-1.42(m,1H),1.30-1.22(m,1H),1.09(s,3H),1.07(s,3H),0.93(s,3H),0.88(s,3H).

[0504] Compound 138 was prepared from intermediate s9.

[0505] LCMS: m / z = 529.50 [M+1] + ; m / z = 527.50 [M-1] + ;

[0506] 1 H NMR (400MHz, CD3OD) δ7.73-7.70(m,1H),7.44(d,J=9.6Hz,1H),5.35-5.33(m,1H ),4.77(d,J=9.6Hz,1H),4.12(s,1H),4.08-4.01(m,2H),3.92-3.88(m,1H),3.31 -3.10(m,3H),2.37-2.30(m,2H),2.18-2.10(m,1H),1.87-1.75(m,1H),1.64-1.6 0(m,1H),1.43-1.40(m,1H),1.18(s,9H),1.07(s,6H),0.93(s,3H),0.88(s,3H).

[0507] Compound 152 was prepared from intermediate s7.

[0508] LC-MS [M+H] + =564.1

[0509] 1 H NMR (400MHz, DMSO-d6) δ9.03 (d, J = 9.7 Hz, 1H), 8.20-8.14 (m, 2H), 5.05-4.98 (m, 1H), 4.90 (d, J = 12. 3Hz,1H),4.52(d,J=9.2Hz,1H),4.04-4.00(m,2H),3.95-3.91(m,1H),3.77(d,J=10.5Hz,1H),3.55 -3.50(m,1H),2.80–2.64(m,1H),2.25–2.17(m,1H),1.90–1.81(m,1H),1.73–1.57(m,3H),1.37(d, J=7.7Hz,1H),1.23(s,1H),1.15(s,3H),1.02(s,3H),0.91(s,3H),0.81(s,3H),0.64-0.59(m,4H).

[0510] Compound 153 was prepared from intermediate s7.

[0511] LCMS: m / z = 528.3 [M+1] + ;

[0512] 1H NMR (400MHz, DMSO-d6) δ9.04(d,J=9.6Hz,1H),8.20(s,1H),7.92(d,J=9.2Hz,1H),5.05-4.99(m,1H),4.78(d,J =12.4Hz,1H),4.48(d,J=8.8Hz,1H),4.04-4.00(m,2H),3.92-3.85(m,2H),3.36(d,J=12.0Hz,1H),2.68-2.62( m,1H),2.29–2.17(m,2H),2.12–1.99(m,2H),1.87–1.79(m,1H),1.69–1.59(m,1H),1.58-1.55(m,1H),1.33(d, J=7.6Hz,1H),1.09(s,3H),1.02(s,3H),0.90-0.85(m,4H),0.84(s,3H),0.41-0.33(m,2H),0.16-0.05(m,2H).

[0513] Compound 157 was prepared from intermediate s7.

[0514] LCMS: m / z = 514.3 [M+1] +

[0515] Compound 177 was prepared from intermediate s10.

[0516] 1 HNMR(400MHz,chloroform-d)δ8.81(br s,1H),6.75(br s,1H),5.08-5.06(m,1H),4.61(d,J=7.6Hz,1H),4.59-4.40(m,2H),4.01-3.90(m,2H),3.64–3.51(m,2H),3 .11(s,3H),2.60-2.20(m,3H),1.90-1.70(m,2H),1.50–1.40(m,2H),1.09(s,6H),1.05(s,3H),0.92(s,3H).

[0517] LC-MS [M+H] + =555.4

[0518] Example 1.10 Synthesis of Compound 125

[0519] To a solution of intermediate s7 (20.0 mg, 44.89 μmol) and 2,2-difluoro-3-phenylpropionic acid in DMF (1 mL) was added HATU (34.14 mg, 89.78 μmol) and DIEA (17.41 mg, 134.68 μmol). The mixture was stirred at 25 ° C for 2 hours. The suspension was concentrated and purified by preparative HPLC (0.04% TFA, acetonitrile / water = 40%-65%) to give compound 125 (8.15 mg, 55%).

[0520] 1 HNMR (400MHz, CDCl3) δ8.28(d,J=7.2Hz,2H),7.28-7.26(m,5H),6.77(d,J=8.4Hz,1H),6.56(d,J=7.6Hz,1H),6.14(s,1H),4.75(m,1H),4. 52-3.74(m,4H),3.52-3.16(m,4H),2.68(m,1H),2.43-2.17(m,3H),1 .68-1.35(m,2H),1.12(s,3H),0.98(s,3H),0.89(s,3H),0.72(s,3H).

[0521] LC-MS [M+H] + =614.4

[0522] Example 1.11 Synthesis of Compound 160

[0523] To a DMF (1.0 mL) solution of s7 (10 mg, 22.45 μmol) and 2,2-difluoro-2-(4-fluorophenyl)acetic acid (6 mg, 31.56 μmol) was added DIEA (10 mg, 77.38 μmol) and HATU (16 mg, 42.08 μmol). The mixture was stirred at 20 ° C for 2 hours. The mixture was diluted with ethyl acetate (10 mL) and washed with saturated NH4Cl (5 mL). The organic layer was separated and concentrated. The residue was purified by preparative HPLC (additive: 0.04% TFA, acetonitrile / water = 45%-65%) to give compound 160 (1.50 mg, 10.67%).

[0524] LC-MS [M+H]+ = 618.20.

[0525] 1H NMR (400MHz, CD3OD) δ7.67-7.63(m,2H),7.23-7.18(m,2H),5.15-5.08(m,1H),4.91(d,J=12.4 Hz,1H),4.68-4.64(m,1H),4.12(d,J=9.6Hz,1H),4.05-3.95(m,2H),3.76-3.70(m,1H),3.36( d,J=12.0Hz,1H),3.09-3.00(m,1H),2.46-2.38(m,2H),2.03-1.93(m,1H),1.83-1.76(m,1H), 1.66-1.59(m,1H),1.38(d,J=8.0Hz,1H),1.25(s,3H),1.04(s,3H),0.90(s,3H),0.68(s,3H).

[0526] The following compounds were prepared following similar chemical reactions and procedures as described above.

[0527] Compound 97 was prepared from intermediate s8.

[0528] LC-MS[M+1] + =556.20

[0529] 1 H NMR(400MHz,DMSO-d6)δ9.62(d,J=8.8Hz,1H),9.15(d,J=9.3Hz,1H),8.13(s,1H),5.00-4 .94(m,1H),4.47–4.35(m,2H),4.15(s,1H),4.06(d,J=8.8Hz,1H),4.01–3.90(m,2H),3.68 -3.65(m,1H),2.48–2.42(m,1H),2.30–2.19(m,2H),2.13–2.03(m,2H),1.69-1.61(m,1H), 1.60–1.51(m,2H),1.35-1.30(m,1H),1.01(s,3H),0.92(s,3H),0.88(s,3H),0.81(s,3H).

[0530] Example 1.12 Synthesis of Compound 159

[0531] To a solution of s7 (128.0 mg, 287.31 μmol) and DIEA (74.26 mg, 574.63 μmol) in DCM (1 mL) was added methyl chlorocarbonate (36.78 mg, 389.21 μmol), and the mixture was stirred at 20° C. for 10 minutes. The reaction solution was concentrated, and the residue was purified by preparative HPLC (0.1% FA, acetonitrile / water=30%-50%) to give compound 159 (32.26 mg, 22%).

[0532] LC-MS [M+H] + =504.3

[0533] 1 HNMR(400MHz,DMSO-d6)δ9.03(d,J=8Hz,1H),8.18(s,1H),7.18(s,1H),5.01(m,1H),4.80-4.77(m,1H),4.10-3.82(m,5H),3.51(s,3H),3.35- 3.31(m,1H),2.70-2.67(m,1H),2.28-2.25(m,2H),1.66-1.55(m,3H), 1.34-1.32(m,1H),1.25(s,3H),1.10(s,3H),1.00(s,3H),0.81(s,3H).

[0534] Compound 156 was prepared from intermediate s7.

[0535] LC-MS [M+H] + =530.30.

[0536] Example 1.13 Synthesis of Compound 98

[0537] To a solution of s8 (70 mg, 152.33 μmol) in DCM (2 mL) was added DIEA (59.06 mg, 456.98 μmol) and methyl chlorocarbonate (21.59 mg, 228.49 μmol), and the mixture was stirred at 15° C. for 1 hour. The residue was purified by preparative HPLC (0.1% TFA, 45%-60% ACN) to give compound 98 (26 mg, 33%).

[0538] LC-MS[M+1] + =518.30

[0539] 1H NMR (400MHz, DMSO-d6) δ9.13(d,J=9.2Hz,1H),8.13(s,1H),7.27(d,J=9.2Hz,1H),4.99-4.93 (m,1H),4.36-4.31(m,1H),4.14(s,1H),4.09–4.02(m,2H),3.99–3.92(m,1H),3.88-3.82(m,2 H),3.51(s,3H),2.44–2.30(m,1H),2.30–2.18(m,2H),2.12–1.98(m,2H),1.67-1.59(m,1H), 1.57–1.43(m,2H),1.26(d,J=7.6Hz,1H),1.01(s,3H),0.88(s,3H),0.86(s,3H),0.85(s,3H).

[0540] Example 2

[0541] Biochemical assays

[0542] Assay 1: Inhibition of 3CLpro

[0543] The test compound was diluted 3 times to obtain 10 doses and added to the assay plate (384w format) in duplicate wells using ECHO. 25 μL of 3CLpro protein was then added to the assay plate containing the compound using Multidrop. The mixture of compound and 3CLpro protein was pre-incubated for 30 minutes at room temperature. 5 μL of substrate was then added using Multidrop. The final concentrations of 3CLpro and substrate were 25 nM and 25 μM, respectively. For the 100% inhibition control (HPE, hundred percent effect), 1 μM GC376 was added. For the non-inhibition control (ZPE, zero percent effect), no compound was added. The final DMSO concentration was 1%. Each active test point had an associated background control to normalize the fluorescence interference of the compound. After incubation for 60 minutes at 30°C, the fluorescence signal (RFU) was detected using an ELISA reader M2e (SpectraMax) at Ex / Em=340nm / 490nm. The inhibitory activity was calculated using the following formula: Inhibition % = [(sample - average ZPE) / (average HPE - average ZPE)] * 100%,

[0544] HEP: 100% efficacy control. Contains substrate + assay buffer + 1 μM GC376.

[0545] ZPE: Zero Percent Effect Control. Contains enzyme + substrate, no compound.

[0546] Sample: Compound activity test well. Contains compound + enzyme + substrate.

[0547] BG: Compound background control wells. Contains compound + substrate, no enzyme.

[0548] IC 50 The inhibition curves were determined and the results are shown in Table 1.

[0549] Assay 2: Human Liver Microsome (HLM) Stability

[0550] The test sample was prepared at 10 mM in DMSO and diluted to 100 μM with ACN:H2O=1:1 (v / v) to obtain a working solution. The working solution was diluted to 1 μM in potassium phosphate buffer (100 mM, pH 7.4) with a final volume of 200 μL and incubated in a 37°C shaker containing MgCl2 (3 mM), NADPH (1 mM) and HLM (1 mg / mL). Incubation was performed in the absence and presence of the selective CYP3A inhibitor ketoconazole (1 μM). The incubation was terminated by adding 200 μL of acetonitrile (300 ng / mL tolbutamide) to 100 μL of sample at selected time points (0 min, 5 min, 15 min, 30 min, 45 min, 60 min, 80 min). The quenched samples at each time point were mixed for 5 minutes and centrifuged at 3700 rpm for 15 minutes. The supernatant was transferred to a 96-well plate, mobile phase A was added to the samples, and analyzed by LC-MS / MS. Half-life (t 1 / 2 ) is estimated to be t 1 / 2 = -0.693 / k and are shown in Table 1, where k is the slope of the linear regression fit of the peak area versus the natural logarithm of time.

[0551] Assay 3: In vitro antiviral activity of anti-OC43

[0552] In vitro anti-OC43 activity and cytotoxicity were evaluated using Huh7 cells as described below.

[0553] Antiviral activity assay: Huh7 cells were seeded in 96-well plates at a density of 8000 cells / well, 100 μL of assay medium per well, and cultured at 37°C and 5% CO2. After 24 hours of incubation, the test compound and positive control (PF-07321332) were diluted with assay medium and then added to the cells, 50 μL per well. Then 50 μL of virus diluted in assay medium was added to each well. The resulting cell culture was incubated for another 7 days until the virus infection in the virus control (virus-infected cells, no compound treatment) showed significant CPE (cytopathic effect). CPE was measured by CellTiter Glo according to the manufacturer's manual. The antiviral activity of the compound was calculated based on the protection against virus-induced CPE at each concentration normalized to the virus control.

[0554] Inhibition % was calculated by the following equation: Inhibition (%) = (raw data CPD - average VC) / (average CC - average VC) * 100.

[0555] Cytotoxicity assay: The cytotoxicity of the compounds was assessed in the same manner as the antiviral activity assay, but without the viral infection step. Huh7 cell viability was measured using Cell-Titer Glo according to the manufacturer's manual. Viability % was calculated by the following equation: Viability (%) = (raw data CPD - average MC) / (average CC - average MC) * 100.

[0556] Raw Data CPD: Value of sample treatment wells.

[0557] Mean VC: Mean value of virus control

[0558] Average CC: average value of cell control (cells without virus infection or compound treatment)

[0559] Mean MC: Mean of medium control (medium only) wells.

[0560] Assay 4: In vitro antiviral activity of anti-229E

[0561] In vitro anti-229E activity and cytotoxicity were evaluated using MRC5 cells as described below.

[0562] Antiviral activity assay: MRC5 cells were seeded in 96-well plates at a density of 20,000 cells / well, 100 μL of assay medium per well, and cultured at 37°C and 5% CO2. After 24 hours of incubation, the test compound and positive control (PF-07321332) were diluted with assay medium and then added to the cells, 50 μL per well. 50 μL of virus diluted in assay medium was then added to each well. The resulting cell culture was incubated for another 3 days until viral infection in the virus control (virus-infected cells, no compound treatment) showed significant CPE. CPE was measured by CellTiter Glo according to the manufacturer's manual. The antiviral activity of the compound was calculated based on the protection of virus-induced CPE at each concentration normalized to the virus control.

[0563] Inhibition % was calculated by the following equation: Inhibition (%) = (raw data CPD - average VC) / (average CC - average VC) * 100.

[0564] Cytotoxicity assay: The cytotoxicity of the compounds was assessed in the same manner as the antiviral activity assay, but without the viral infection step. Cell viability was measured using Cell-Titer Glo according to the manufacturer's manual. Viability % was calculated by the following equation: Viability (%) = (raw data CPD - average MC) / (average CC - average MC) * 100.

[0565] Raw data CPD: value of sample treatment well

[0566] Mean VC: Mean value of virus control

[0567] Average CC: average value of cell control (cells without virus infection or compound treatment)

[0568] Mean MC: Mean of medium control (medium only) wells.

[0569] Assay 5: In vitro antiviral activity against SARS-CoV-2 replicons

[0570] The compounds were serially diluted in DMSO and added to 384-well plates at 0.3 μL per well (8 doses, 3 times, duplicate wells). Replicon RNA was produced in vitro transcripts. Huh7 cells transfected with purified SARS-CoV-2 replicon RNA were seeded at 4000 / well in 384 microplates containing serially diluted compounds and then cultured for 1 day at 37°C and 5% CO2. The final volume of the cell culture was 60 μL / well, and the final concentration of DMSO in the test plate was 0.5%.

[0571] Fluorescence intensity was determined using Acumen Cellista (TTP LabTech), and the antiviral activity of the compounds was calculated based on the inhibition of GFP expression. Cell viability was measured using CellTiter Glo according to the manufacturer's manual.

[0572] The antiviral activity and activity of the compounds were expressed as % inhibition and % activity, respectively, and were calculated using the following formula:

[0573] Inhibition (%) = (raw data CPD - average ZPE) / (average HPE - average ZPE) * 100

[0574] Vitality (%) = (original data CPD - average HPE) / (average ZPE - average HPE) * 100

[0575] Raw data CPD: value of sample treatment well

[0576] Average ZPE: average of virus control

[0577] Mean HPE: Mean of medium control (medium only) wells.

[0578] EC50 values ​​and CC50 values ​​were calculated using GraphPad Prism software using a nonlinear regression model of log(inhibitor) vs. response—variable slope (four parameters), and the results are shown in Table 1.

[0579] Assay 6: In vitro antiviral activity against SARS-CoV-2

[0580] In vitro anti-SARS-COV-2 activity and cytotoxicity were evaluated using Vero cells as described below.

[0581] Antiviral activity assay: Vero cells were seeded in 96-well plates at a density of vero cells / well, 100 μL of assay medium per well, and cultured at 37°C and 5% CO2. After 24 hours of incubation, the test compound and positive control (PF-07321332) were diluted with assay medium and then added to the cells, 50 μL per well. 50 μL of virus diluted in assay medium was then added to each well. The resulting cell culture was incubated for another 3 days until viral infection in the virus control (virus-infected cells, no compound treatment) showed significant CPE. CPE was measured by CellTiter Glo according to the manufacturer's manual. The antiviral activity of the compound was calculated based on the protection of virus-induced CPE at each concentration normalized to the virus control.

[0582] Inhibition % was calculated by the following equation: Inhibition (%) = (raw data CPD - average VC) / (average CC - average VC) * 100.

[0583] Cytotoxicity assay: The cytotoxicity of the compounds was assessed in the same manner as the antiviral activity assay, but without the viral infection step. Cell viability was measured using Cell-Titer Glo according to the manufacturer's manual. Viability % was calculated by the following equation: Viability (%) = (raw data CPD - average MC) / (average CC - average MC) * 100.

[0584] Raw data CPD: value of sample treatment well

[0585] Mean VC: Mean value of virus control

[0586] Average CC: average value of cell control (cells without virus infection or compound treatment)

[0587] Mean MC: Mean of medium control (medium only) wells.

[0588] Table 1

[0589]

[0590]

[0591] *IC 50 (nM): A<100, B 100-1000, C>1000

[0592] **EC 50 (nM): A<100, B 100-1000, C>1000

[0593] ***Liver microsomal T 1 / 2 (min): A>100, B£100

[0594] The foregoing description is considered to be merely an illustration of the principles of the present disclosure. In addition, since many modifications and variations are apparent to those skilled in the art, it is not desirable to limit the present invention to the exact configuration and process as described above. Therefore, all suitable modifications and equivalents are considered to fall within the scope of the present invention as defined by the appended claims.

Claims

1. Use of a compound or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating viral infection, in, The compound is selected from the group consisting of: A wavy line directly connected to a double bond indicates that the double bond is in the E or Z configuration.

2. The use according to claim 1, in, The virus is SARS-COV-2.

Citation Information

Patent Citations

  • Virus main protease inhibitor as well as preparation method and application thereof

    CN113773259A

  • Methods of inhibiting SARS-cov-2 replication and treating coronavirus disease 2019

    TW202146012A

  • Compounds and pharmaceutical uses thereof

    US20210251945A1

  • Use of masitinib for the treatment of coronavirus disease 2019 (covid-19)

    WO2021205029A1

Cited By

  • Application of small molecule compound Y020-0023 in resisting SARS-CoV-2 infection

    CN119925366A

  • Application of a small molecule compound Y020-0023 in anti-SARS-CoV-2 infection

    CN119925366B